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Abstract 
Hereditary hemochromatosis (HH) is a group of primary genetic disorders of iron 
homeostasis. HFE-HH, the most common form of HH in populations of northern 
European ancestry, is mainly caused by a C282Y mutation in the HFE gene. HH is 
characterized by hyperabsorption of dietary iron, which is delivered to plasma leading to 
increased transferrin saturation and tissue iron accumulation. The liver accumulates 
large amounts of iron and the excess free iron is capable of generating reactive oxygen 
species, which damage the tissue. NRF2 is the key transcription factor involved in the 
antioxidant response, so we hypothesized that it can act as a modifier of the clinical 
expression of HH. In this study, we aimed to: i) determine the effect of Nrf2 suppression 
in a model of chronic iron overload that mimics HH, the Hfe-/- mouse; ii) identify 
polymorphisms/genotypes in the human NRF2 gene promoter that may influence HH 
penetrance in HFE C282Y+/+ patients. Female WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice on 
a C57BL/6J background at 24 months of age were fasted overnight for blood and organ 
collection. Aged Nrf2/Hfe-/- mice presented lower body weight, mild anemia and 
hypoglycemia at starvation. Mild liver inflammation was detected in mice of the four 
genotypes, possibly as a consequence of aging. NRF2 proved to be essential in the 
antioxidant defense, as Nrf2-/- and Nrf2/Hfe-/- mice presented decreased levels of Nqo1 
transcript and the GSH/GSSG ratio was significantly decreased in Nrf2-/- livers. Despite 
the similar amount of non-heme iron in Hfe-/- and Nrf2/Hfe-/- livers, we observed a shift in 
the local deposition of iron from the liver parenchyma (in Hfe-/- mice) to sinusoidal cells 
(in Nrf2/Hfe-/- mice). Necrosis, fibrosis and the number of TUNEL-positive cells were 
augmented in Nrf2/Hfe-/- livers. Overall, we conclude that the suppression of NRF2 leads 
to spontaneous liver damage in Hfe-/- mice, the mouse model of HH. In the human study, 
DNAs of patients HFE C282Y+/+ were genotyped for Rs35652124, Rs670664, 
Rs150648896 and Rs6721961 SNPs in the NRF2 promoter region. Our results indicate 
that none of the SNPs alone prompts the patients to develop a specific clinical 
manifestation, but patients carrying the allele C in Rs35652124 SNP are somehow 
protected from clinical manifestations of HH. In conclusion, the current study shows that 
NRF2 has an important hepatoprotective role in the animal model of HH and suggests 
that gene variants may be also implicated in the clinical course of the human disease. 
 
Keywords: Aging, Iron, Hereditary Hemochromatosis, Hfe, Nrf2. 
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Resumo 
A hemocromatose hereditária (HH) é um grupo de doenças genéticas primárias de 
homeostasia do ferro. Na população originária do norte da Europa, a HFE-HH é a forma 
mais comum de HH, sendo principalmente causada pela mutação C282Y no gene HFE. 
A HH é caracterizada por hiperabsorção de ferro da dieta, que entra na corrente 
sanguínea e leva ao aumento da saturação da transferrina e da acumulação de ferro 
nos tecidos. O fígado acumula grandes quantidades de ferro, capaz de gerar espécies 
reactivas de oxigénio que danificam o tecido. Como o NRF2 é o fator de transcrição 
chave da resposta antioxidante, pensámos que este pode ser um modificador da 
expressão clínica da HH. Os objetivos do nosso estudo foram: i) determinar o efeito da 
supressão do Nrf2 num modelo de sobrecarga de ferro crónica que imita a HH, o 
murganho Hfe-/-; ii) identificar polimorfismos/genótipos no promotor do gene NRF2 
humano, que possam influenciar a penetrância da HH em pacientes C282Y+/+. Foram 
recolhidos órgãos e sangue de murganhos fêmea WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- com 
24 meses de idade. Os murganhos Nrf2/Hfe-/- velhos tinham baixo peso corporal, anemia 
ligeira e hipoglicemia em jejum. Nos murganhos dos quatro genótipos observou-se 
inflamação hepática ligeira, possivelmente devida ao envelhecimento. O NRF2 provou 
ser essencial na defesa antioxidante, uma vez que os murganhos Nrf2-/- e Nrf2/Hfe-/- 
apresentaram níveis diminuídos de transcrito do gene Nqo1 e que a razão GSH/GSSG 
se encontrou significativamente diminuída nos fígados Nrf2-/-. Apesar da semelhante 
quantidade de ferro não-heme em fígados Hfe-/- e Nrf2/Hfe-/-, observámos uma alteração 
no local de deposição do ferro do parênquima do fígado (em murganhos Hfe-/-) para as 
células sinusoidais (em murganhos Nrf2/Hfe-/-). A necrose, a fibrose e o número de 
células TUNEL-positivas estavam aumentados nos fígados Nrf2/Hfe-/-. Concluímos que 
a supressão do NRF2 leva a um dano hepático espontâneo no murganho Hfe-/-, o 
modelo animal da HH. No estudo humano, DNAs de pacientes HFE C282Y+/+ foram 
genotipados para os SNPs Rs35652124, Rs670664, Rs150648896 e Rs6721961 na 
região promotora do NRF2. Os nossos resultados indicam que nenhum SNP, por si só, 
leva ao desenvolvimento de uma manifestação clínica, mas pacientes portadores do 
alelo C no SNP Rs35652124 estão de alguma forma protegidos das manifestações da 
HH. Concluindo, o presente estudo mostra que o NRF2 tem um papel hepatoprotetor 
importante no modelo animal da HH e que as variantes genéticas podem estar 
implicadas no curso clínico da doença humana. 
 
Palavras-chave: Envelhecimento, Ferro, Hemocromatose Hereditária, Hfe, Nrf2. 
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Introduction 
 
1. Iron metabolism 
Iron is essential for nearly all living organisms and plays an important role in several 
biochemical activities, such as oxygen sensing and transport, electron transfer, catalysis, 
energy production and DNA synthesis (Evstatiev and Gasche, 2012; Ganz, 2013; 
Papanikolaou and Pantopoulos, 2005). Iron is capable of accepting or donating 
electrons, switching between ferrous (Fe2+) and ferric (Fe3+) forms (Andrews, 1999; 
Evstatiev and Gasche, 2012; Papanikolaou and Pantopoulos, 2005). The redox potential 
of free iron can trigger the Fenton or Haber-Weiss reactions, which catalyze the 
production of toxic reactive oxygen species (ROS) (Evstatiev and Gasche, 2012; Lane 
et al., 2015; Papanikolaou and Pantopoulos, 2005). As ROS may damage DNA, proteins 
and lipid membranes (Andrews, 1999; Evstatiev and Gasche, 2012), iron is usually 
incorporated into proteins and prosthetic groups (Evstatiev and Gasche, 2012; Silva and 
Faustino, 2015). The intracellular iron content is thus tightly controlled through the 
regulation of iron import, storage and efflux (Evstatiev and Gasche, 2012; Lane et al., 
2015; Yun and Vincelette, 2015). 
 
1.1. Body iron distribution 
The average adult human has 3-5 g of iron in the body, depending on gender and age 
(Evstatiev and Gasche, 2012; Ganz, 2013; Gkouvatsos et al., 2012). Over 2 g of iron are 
incorporated in the hemoglobin and the remaining iron is either stored in hepatocytes 
(~1000 mg) or circulates in a transit pool in reticuloendothelial macrophages (~600 mg). 
Iron can also be found in myoglobin (~300 mg), in iron-containing proteins (~8 mg) or 
circulating in the plasma bound to transferrin (~3 mg) (Andrews, 1999; Gkouvatsos et 
al., 2012; Papanikolaou and Pantopoulos, 2005) (Figure 1). 
 
1.2. Intestinal iron absorption 
The regulation of iron absorption is a key element in iron homeostasis since there is no 
pathway for its excretion (Andrews, 1999; Gkouvatsos et al., 2012). Iron absorption (1-2 
mg per day) takes place in the enterocytes of the duodenum and in the upper jejunum 
(Andrews, 1999; Evstatiev and Gasche, 2012). This serves to compensate for the daily 
loss of iron (1-2 mg per day) through sweating, desquamation of epithelial surfaces and 
bleeding, thus contributing modestly to the total iron demand in the body (Ganz, 2013; 
Gkouvatsos et al., 2012) (Figure 1). However iron absorption can be enhanced, when 
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the body has higher needs of iron, or suppressed in cases of iron overload (Hentze et 
al., 2010). 
Iron is essentially absorbed from food. There are two distinct forms of dietary iron that 
appear to be absorbed by separate mechanisms: heme iron and inorganic iron (non-
heme iron) (Sharp, 2010; Wyllie and Kaufman, 1982). Heme, a protoporphyrin ring that 
binds iron (Dunn et al., 2007), is very abundant in meat products (Silva and Faustino, 
2015) and is more bioavailable than the non-heme form (Gkouvatsos et al., 2012). Heme 
is released from hemoproteins in the stomach due to the low pH and to proteolytic 
enzymes (Silva and Faustino, 2015). Although the mechanism of heme uptake is not yet 
well characterized, it is known to occur via direct transport (Gkouvatsos et al., 2012) or 
via receptor-mediated endocytosis (Ganz, 2013; Silva and Faustino, 2015). A putative 
candidate for heme transporter in the enterocyte is heme carrier protein 1 (HCP1) 
(Shayeghi et al., 2005). HCP1, together with the proton coupled folate transporter 
(PCFT) (Silva and Faustino, 2015), is capable of internalizing heme. However, HCP1 
affinity to heme is low (Laftah et al., 2009) and its nonredundant fuction is folate uptake 
in the duodenum (Ganz, 2013), revealing that HCP1 is not essential for duodenal heme 
uptake. Once inside the enterocyte, heme can migrate to the endoplasmatic reticulum 
(Dunn et al., 2007), where heme oxygenase-1 (HO-1) localized in the reticulum surface 
liberates ferrous iron, carbon monoxide and biliverdin from heme (Gkouvatsos et al., 
2012; Silva and Faustino, 2015). Fe2+ can then follow the fate of inorganic iron. Heme 
can also be exported as an intact molecule via the putative heme exporter feline 
leukemia virus, subgroup C, receptor (FLVCR) (Khan and Quigley, 2011). 
Non-heme iron, including iron-sulfur clusters, is present in the intestinal lumen in its 
insoluble oxidized Fe3+ form (Gkouvatsos et al., 2012). In order to be absorbed by the 
enterocyte, Fe3+ is reduced in the apical membrane by brush border reductases (Silva 
and Faustino, 2015). Duodenal cytochrome b (DCYTB) (McKie et al., 2001) was the first 
ferrireductase discovered and it uses ascorbate for the reduction reaction (Andrews and 
Schmidt, 2007). However, DCYTB proved not to be essential for the reduction of Fe3+ to 
Fe2+ (Gunshin et al., 2005). This suggests the existence of other ferrireductases, like six 
transmembrane epithelial antigen of the prostate 2 (STEAP2) (McKie et al., 2001; 
Ohgami et al., 2006). The reduced Fe2+ iron is transported across the apical membrane 
by the proton-coupled divalent metal transporter 1 (DMT1, SLC11A2, NRAMP2 or 
DCT1). DMT1 is a 12-transmembrane-segment protein that uses the proton gradient, 
generated by the intestinal Na+/H+ exchanger (Mackenzie et al., 2011), between the gut 
lumen and the enterocyte cytoplasma to perform the symport of Fe2+ coupled with H+ 
(Gunshin et al., 1997), but it is not specific to iron (Andrews, 1999). 
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Figure 1. Iron distribution in the human body. Per day, 1-2 mg of iron enters and leaves the body. Dietary iron is absorbed 
by duodenal enterocytes and circulates bound to plasma transferrin. Most of the iron is incorporated into hemoglobin in 
erythroid precursors and mature red blood cells. The remaining iron is present in muscle fibers, in myoglobin, in 
parenchymal cells of the liver and in reticuloendothelial macrophages. Adapted from (Papanikolaou and Pantopoulos, 
2005). 
 
Inside enterocytes, the new acquired Fe2+ obtained from heme or non-heme iron has 
the same fate: it may be stored in ferritin, it can enter the hypothesized intracellular or 
“labile” iron pool (Dunn et al., 2007), it may be used for metabolic purposes (mainly by 
mitochondria) or it can be exported through the enterocyte basolateral membrane into 
the circulation (Papanikolaou and Pantopoulos, 2005) (Figure 2). 
 
1.3. Iron storage 
In order to prevent cell damage through the production of ROS, the excess of iron in the 
cell is stored in an inert form – bound to ferritin. Cytoplasmic ferritin, a spherical nanocage 
protein with 24 units of ferritin heavy and light chains (Evstatiev and Gasche, 2012), is 
capable of storing large amounts of iron (Ganz, 2013). Ferrous iron is delivered by poly 
(rC)-binding protein (PCBP1) to ferritin and ferritin heavy chain oxidizes Fe2+ to Fe3+ 
(Ganz, 2013). Mitochondrial ferritin (Levi et al., 2001), another form of ferritin very similar 
to cytoplasmic ferritin, is also capable of storing iron, playing a protective role in 
conditions of iron overload (Richardson et al., 2010). Liver hepatocytes generally store 
20-30% of the total body iron, mostly in the form of ferritin (Andrews and Schmidt, 2007). 
This renders the liver a crucial function in iron storage. 
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Figure 2. Heme and non-heme iron uptake, utilization and export by enterocytes. Heme iron enters the enterocyte via 
heme carrier protein 1 (HCP1) and Fe2+ is released after the breakup of heme by hemoxygenase (HO-1). Non-heme iron 
enters via divalent metal transporter 1 (DMT1), after a reduction step by duodenal cytochrome B (DCYTB). Ferrous iron 
can enter the labile iron pool, can be stored in ferritin, can be used by mitochondria or can be exported via ferroportin. 
Exported Fe2+ is oxidized by hephaestin and bound to transferrin (Tf). Adapted from (Evstatiev and Gasche, 2012). 
 
Plasma ferritin, a soluble but iron-poor form of ferritin, contains mostly light chains and 
is derived primarily from macrophages (Cohen et al., 2010). Serum concentrations of 
ferritin correlate to body iron stores, and are thus considered an important clinical 
parameter. While it is still unknown how ferritin enters the circulation and what is its exact 
function, it is speculated that plasma ferritin acts like an iron scavenger, reducing 
oxidative stress (Evstatiev and Gasche, 2012). 
 
1.4. Iron export 
A crucial step for the entrance of iron in the body is the export of cytosolic iron into the 
circulation by ferroportin (FPN1 (Donovan et al., 2000), SLC40A1, IREG1 (McKie et al., 
2000), MTP1 (Abboud and Haile, 2000)) (Gkouvatsos et al., 2012). Ferroportin, a 12-
transmembrane domain protein, is the only known mammalian iron exporter (Ganz, 
2013). It is expressed in the basolateral membranes of duodenal enterocytes, in the 
membranes of macrophages (Canonne-Hergaux et al., 2006) and in the sinusoidal 
surfaces of hepatocytes (Ramey et al., 2010). The export of iron requires ferroxidases, 
such as plasma ceruloplasmin, present in macrophages and hepatocytes membranes, 
(Healy and Tipton, 2007) and enterocyte membrane-bound hephaestin (Vulpe et al., 
1999), that use oxygen to re-oxidize Fe2+ to Fe3+ (Ganz, 2013). Fe3+ can then be loaded 
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into the circulatory transferrin (Tf) to be delivered to cells or can circulate as non-
transferrin bound iron (NTBI). 
 
1.5. Iron transport and uptake 
1.5.1. Transferrin-dependent mechanisms 
Transferrin, a 75 to 80-kDa glycosylated protein, is an extracellular iron carrier (Ganz, 
2013). Tf has two high-affinity binding sites for Fe3+ (Hentze et al., 2010) and circulates 
in the plasma in three states: apo-transferrin (apo-Tf), when no iron is bound; monoferric 
transferrin, bound to one Fe3+; diferric transferrin, also known as holo-transferrin (holo-
Tf), bound to two Fe3+ (Young and Bomford, 1984). Transferrin saturation is used as a 
clinical parameter: <16% indicates iron deficiency and >45% indicates iron overload; 
30% is the normal saturation. When transferrin saturation exceeds 60%, NTBI starts to 
accumulate in the circulation, which can damage parenchymal cells (Hentze et al., 2010). 
When bound to Tf, iron is nonreactive but very difficult to extract, so the entire iron-
protein complex is internalized (Hentze et al., 2004). The cellular uptake of transferrin-
bound iron (TBI) is mostly mediated by the transferrin receptor 1 (TfR1), at the cell 
membrane (Brown and Johnson, 1981). TfR1 is a transmembrane glycoprotein 
ubiquitously expressed (Hentze et al., 2004) and can bind one Tf molecule at each 
subunit (Aisen, 2004). The TBI/TfR1 complex undergoes endocytosis via clathrin-coated 
pits (Gkouvatsos et al., 2012). The entry of H+ mediated by an ATP-dependent proton 
pump decreases the endosome pH, causing a conformational change in Tf and the 
release of Fe3+ (Gkouvatsos et al., 2012; Silva and Faustino, 2015). Apo-Tf remains 
bound to TfR1, while free Fe3+ is reduced by six transmembrane epithelial antigen of the 
prostate 3 (STEAP3) and exported to the cytoplasm by DMT1 (Silva and Faustino, 2015). 
Apo-Tf and TfR1 return to the cell surface (Hentze et al., 2004), in a process involving 
the trafficking protein SEC15L1 (Lim et al., 2005). Apo-Tf is then recycled to the 
bloodstream, where it can capture more iron (Gkouvatsos et al., 2012) (Figure 3). 
TBI/Tf uptake is also known to occur via TfR1-independent mechanisms. Transferrin 
receptor 2 (TfR2) (Kawabata et al., 1999), a protein homologous to TfR1, is believed to 
be one of them (Gkouvatsos et al., 2012). TfR2 is mainly expressed in hepatocytes and 
binds holo-Tf with 25-fold lower affinity than TfR1 (Robb et al., 2004). Mutations in TfR2 
cause hereditary hemochromatosis (HH) (Camaschella et al., 2000; Fleming et al., 
2002), a systemic iron overload disease, revealing that this protein is more important for 
the regulation of systemic iron homeostasis rather than for cellular iron uptake 
(Gkouvatsos et al., 2012). 
6 
 
FCUP 
NRF2 protection against liver injury in human and mouse models of HH 
 
Regardless of the existence of several pathways for the uptake of TBI, TfR1-mediated 
endocytosis is crucial for the organism, since it is indispensable for the delivery of iron to 
developing erythroid cells (Gkouvatsos et al., 2012). 
 
 
Figure 3. The Transferrin Cycle. Diferric transferrin (Fe2-Tf) binds to transferrin receptors (TfR) on the cell surface. The 
Tf/TfR complex undergoes endocytosis via clathrin-coated pits, forming a specialized endosome. A proton pump 
decreases the pH within endosomes, what causes conformational changes in Tf and, consequently, the release of Fe3+. 
The iron transporter DMT1 moves iron across the endosomal membrane, to enter the cytoplasm, after a reduction step 
by STEAP3. Apo-Tf and TfR are recycled back to the cell surface, and Apo-Tf is released from TfR to plasma for another 
uptake cycle. Adapted from (Andrews, 1999). 
 
1.5.2. Transferrin-independent mechanisms 
In iron overload conditions, such as HH, transferrin iron binding sites become 
supersaturated and circulating “free” iron increases (Hentze et al., 2004). NTBI is thought 
to circulate in the plasma bound to albumin or small organic acids, like citrate (Hider, 
2002). The exact mechanism of NTBI uptake is still unclear, but it has been suggested 
that one or more cell surface ferrireductases are involved in the process (McKie et al., 
2001). These enzymes reduce Fe3+ NTBI to Fe2+ NTBI, so it can be imported (Lane et 
al., 2015). DMT1 transporter seems to import NTBI (Lane et al., 2015), but the zinc 
transporter Zrt-Irt-like protein 14 (ZIP14) is the most probable NTBI transporter (Liuzzi et 
al., 2006).  
 
1.6. Iron consumption: erythropoiesis 
Two-thirds of the body iron is used by the erythroid bone marrow for erythropoiesis 
(Andrews and Schmidt, 2007). Erythroid precursors highly express transferrin receptors 
at the cell surface, promoting iron uptake via TfR-mediated endocytosis (Hentze et al., 
2004). Once inside the cytoplasm, iron is driven to the mitochondrion via a cytosolic iron 
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chaperon, the PCBP1 (Shi et al., 2008), or directly from the endosome through a “kiss-
and-run” mechanism (Silva and Faustino, 2015). Iron is then transported through the 
inner membrane by mitoferrins 1 and 2 (Paradkar et al., 2009; Shaw et al., 2006) for 
heme synthesis. Ferrous iron is incorporated into protoporphyrin IX by ferrochelatase 
(Evstatiev and Gasche, 2012). Most of the heme is used for hemoglobin production, but 
it can also be exported by FLVCR (Andrews and Schmidt, 2007). 
 
1.7. Iron recycling: macrophages 
Every day, a total of 25 mg of iron are needed for erythropoiesis. However, only 1-2 mg 
of iron enter the body through the enterocytes. Thus, macrophages play a crucial role in 
iron recycling (Hentze et al., 2004), providing nearly all of the available iron. Splenic and 
hepatic macrophages scavenge the senescent erythrocytes (Silva and Faustino, 2015). 
Once inside the phagolysosome, the action of hydrolytic enzymes and ROS releases 
hemoglobin or free heme from the erythrocyte to the vacuolar fluid (Silva and Faustino, 
2015). HO-1, in the presence of O2, cleaves heme to iron, carbon monoxide and biliverdin 
(Poss and Tonegawa, 1997). 
Besides capturing TBI, macrophages are also capable of capturing free hemoglobin 
and free heme from the serum. Free hemoglobin is captured by haptoglobin (Kristiansen 
et al., 2001), a liver derived plasma protein. CD163 receptor recognizes this complex 
and promotes its endocytosis in the macrophage (Van Gorp et al., 2010). Free heme, in 
turn, is scavenged by hemopexin (Tolosano et al., 2010) and suffers endocytosis via the 
CD91 receptor (Hvidberg et al., 2005), which is not only present in the surface of 
macrophages but also in hepatocytes and other cell types (Gkouvatsos et al., 2012). 
There is a putative candidate for heme transport in macrophages, the heme responsive 
gene 1 (HRG1) (Rajagopal et al., 2008). HRG1, described in Caenorhabditis elegans, 
seems to be involved in the uptake of heme released by senescent erythrocytes (Ganz, 
2013), in the phagolysosomes of macrophages (Delaby et al., 2012). Both free heme 
and free hemoglobin endocytosed by the macrophages are hydrolyzed and contribute to 
the iron pool (Caza and Kronstad, 2013) (Figure 4). 
 
1.8. Control of cellular iron homeostasis 
Cellular iron homeostasis is regulated by a post-transcriptional mechanism that controls 
the synthesis of proteins involved in iron uptake, storage and release (Muckenthaler et 
al., 2008). This mechanism depends on two iron regulatory proteins (IRP): IRP1 and IRP 
2, which post-transcriptionally control the expression of iron responsive element (IRE) 
containing mRNAs (Muckenthaler et al., 2008). IREs are located in the 5’ untranslated 
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region (UTR) of the mRNAs enconding TfR1, DMT1 and in the 3’ UTR of ferritin and 
ferroportin mRNAs. In iron-depleted cells, IRPs either bind to 5’ IRE, suppressing the 
translation of FPN1 and ferritin mRNAs, or to 3’ IRE, enhancing TfR1 and DMT1 mRNA 
stability and thus preventing its degradation. On the other hand, in iron-replete cells, 
IRP1 and IRP2 are inactivated. TfR1 and DMT1 mRNAs suffer degradation and FPN1 
and ferritin mRNAs undergo translation. This response promotes the detoxification of 
excess intracellular iron, by iron storage, and inhibits further iron uptake (Papanikolaou 
and Pantopoulos, 2005). 
 
1.9. Control of systemic iron homeostasis 
Systemic iron has to be tightly regulated, so cells have enough iron to suppress their 
needs but also avoid the toxicity associated with iron excess  (Andrews and Schmidt, 
2007). Hepcidin, a 25 amino acid peptide encoded by the HAMP gene, seems to regulate 
the major flows of iron and is in turn regulated by iron (Ganz, 2013). This hormone, which 
circulates in the blood plasma, is primarily produced and secreted by hepatocytes and is 
filtered by the kidneys (Park et al., 2001). Hepcidin post-transcriptionally controls the 
membrane concentration of ferroportin (Nemeth et al., 2004). When iron levels are high, 
hepcidin binds directly to ferroportin, leading to its internalization and degradation within 
lysosomes. As ferroportin is the only mammalian known iron exporter, this mechanism 
blocks the release of dietary, stored and recycled iron from the enterocytes, hepatocytes 
and macrophages, respectively (Nemeth et al., 2004). 
 
 
Figure 4. Iron recycling in macrophages. Senescent erythrocytes are scavenged by macrophages and HO-1 cleaves 
heme to iron. Hemopexin scavenges free heme and suffers endocytocis via the CD91 receptor. Haptoglobin captures free 
hemoglobin and is recognized by the CD163 receptor. HRG1 is a putative heme transporter. Adapted from (Caza and 
Kronstad, 2013). 
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1.9.1. Hepcidin regulation 
Hepcidin is feedback-regulated by iron and this process involves intracellular and 
extracellular iron sensors. Iron sensors are coupled to transduction pathways that 
regulate hepcidin synthesis and secretion by hepatocytes (Ganz and Nemeth, 2012). 
Four of these iron sensors are proteins located at the cell surface: hemojuvelin (HJV), 
hemochromatosis-related membrane protein HFE, TfR1 and TfR2 (Silva and Faustino, 
2015). Thus, hepcidin expression is inhibited in iron deficiency or when high amounts of 
iron are required for erythropoiesis (for example, in anemia or hypoxia) and is enhanced 
when iron stores are replenished or during inflammatory response, when erythropoiesis 
is restrained (Papanikolaou and Pantopoulos, 2005). 
Hepcidin transcription in the liver is regulated by iron levels through two different 
pathways. The first one involves the hemochromatosis-related membrane protein HFE. 
This protein requires interaction with β2-microglobulin for normal presentation on the cell 
surface (Bacon, 1997), where it interacts with TfR1 and TfR2 and functions as a holo-Tf 
sensor (Ganz and Nemeth, 2012). The binding of HFE to TfR1 is competitively inhibited 
by holo-Tf. When transferrin-iron saturation increases, HFE is displaced from TfR1 and 
interacts with TfR2, which can bind both HFE and Fe2-Tf simultaneously (Gao et al., 
2009). The FeTf/HFE/TfR2 complex stimulates hepcidin expression through a mitogen-
activated protein kinases (MAPK) and/or a bone morphogenetic protein (BMP) pathway 
signaling (Ganz and Nemeth, 2012). Conversely, when transferrin-iron saturation is low, 
HFE binds to TfR1 (Muckenthaler, 2014) and hepcidin expression is repressed. A second 
mechanism is the BMP signaling pathway, which is capable of integrating signals from 
the “Tf-Fe-sensing complex” and from hepatocytic iron stores (Hentze et al., 2010). HJV 
is a co-receptor of BMPs (in mice, BMP6) and binds to BMP type 1 and BMP type 2 
receptors on the cell surface. The HJV-BMP6-BMP-receptor complex induces an 
intracellular BMP signaling cascade that activates the SMAD cascade. BMP6 activates, 
by phosphorylation, SMAD1, SMAD5 and SMAD8 proteins (Gkouvatsos et al., 2012). 
Activated p-SMAD1/5/8 interacts with SMAD4 and the whole complex translocates to the 
nucleus. In the nucleus, the complex binds to two BMP responsive elements (BMP-RE1 
and BMP-RE2) at proximal and distal sites of hepcidin promoter, activating its 
transcription (Casanovas et al., 2009) (Figure 5). It is suggested that BMP6 
concentration can reflect the intracellular iron levels, since BMP6 mRNA increases in the 
liver of mice subjected to iron loading (Kautz et al., 2008). 
Hepcidin transcriptional regulation can also occur in inflammatory conditions. 
Interleukin-6 (IL-6), and possibly other inflammatory cytokines, induces the activation of 
the signal transducer and activator of transcription 3 (STAT3). STAT3 binds to a 
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regulatory element in the hepcidin promoter and enhances hepcidin transcription 
(Wrighting and Andrews, 2006). The increase of hepcidin causes hypoferremia, typical 
of the early stages of inflammation and infection, to limit the multiplication of iron-
dependent extracellular microbes (Ganz and Nemeth, 2012). However, iron 
sequestration and hypoferremia may limit the iron available for erythropoiesis, leading to 
anemia of inflammation (anemia of chronic disease) (Ganz and Nemeth, 2012). 
Erythropoietic precursors are the main iron consumers and the expansion of a 
precursor population suppresses hepcidin, allowing the mobilization of iron. The 
existence of an “erythroid regulator” that stimulates iron absorption in response to 
anemia and ineffective erythropoiesis has recently been demonstrated (Kautz et al., 
2014). Erythropoietin (EPO), a glycoprotein hormone synthesized by the kidney, 
prevents the apoptosis of the erythropoietic precursors that have not begun the synthesis 
of hemoglobin (Silva and Faustino, 2015). EPO can directly suppress hepcidin 
expression, by attenuating the binding of the CCAAT/enhancer-binding protein alpha 
(C/EBPα) to the hepcidin promoter (Pinto et al., 2008). Hepcidin is also down-regulated 
by hypoxia. During hypoxia, erythropoiesis increases, in order to overcome the low levels 
of oxygen in the body. The hypoxia inducing factors (HIFs) are suggested to be involved 
in this process through a hypoxia-response elements (HREs)-mediated mechanism 
(Silva and Faustino, 2015). 
 
 
Figure 5. Regulation of hepcidin transcription. In iron deficient state, HFE binds to TfR1 and hepcidin isn’t expressed. In 
iron replete state, HFE is displaced from TfR1 and interacts with TfR2. This interaction stimulates hepcidin expression 
trough MAPK and/or BMP pathway. In iron replete cells, binding of BMP6 to the BMP receptor (BMPR) and to the 
coreceptor HJV also stimulates hepcidin expression. The HJV-BMP6-BMPR complex induces the phosphorylation of 
SMAD 1, 5 and 8. Phospho-SMAD 1, 5, 8 interacts with SMAD 4 and the whole complex translocates to the nucleus and 
binds to BMP-REs, activating hepcidin transcription. Adapted from (Evstatiev and Gasche, 2012). 
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2. Iron metabolism disorders 
Although the body iron homeostasis is tightly controlled, several factors, either genetic 
or environmental, may lead to the development of iron overload or deficiency conditions. 
The iron overload disorders are classified as genetic or acquired. The genetic disorders 
are originated by mutations in iron metabolism genes, while the acquired ones 
correspond to secondary iron overload (Silva and Faustino, 2015). 
 
2.1. Hereditary Hemochromatosis 
Hereditary hemochromatosis (HH) is a group of primary genetic disorders of iron 
homeostasis. The primary cause of HH is often the insufficient production of hepcidin by 
hepatocytes, despite the high amounts of iron present in the body (Silva and Faustino, 
2015). This leads to hyperabsorption of dietary iron, which is delivered to plasma 
resulting in increased Tf saturation and tissue iron accumulation (Pietrangelo, 2010). If 
phlebotomy, the most common treatment for HH, is not applied, iron can cause injury 
and organ dysfunction. The liver, in particular, accumulates large amounts of iron. 
Excess free iron is a potent deleterious hepatotoxic as well as a potential pro-fibrogenetic 
cofactor, since it is capable of generating ROS (Parola and Robino, 2001). In liver 
fibrosis, Kupffer cells (resident liver macrophages) give stimuli for the progression of the 
fibrogenetic process. Hepatic stellate cells (HSC) become “activated” and synthesize 
most of the extracellular matrix (ECM) proteins (Poli and Parola, 1997). The process is 
also accompanied by increased release of cytokines, such as IL-1 and IL-6 (Barbero-
Becerra et al., 2015). The ECM components include collagen, mostly in the form of 
collagen-1, matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) (Barbero-Becerra et al., 2015). TIMP1 is considered an 
important promoter of liver fibrosis (Fowell et al., 2011) and an inhibitor of activated HSC-
apoptosis (Murphy et al., 2002). Fibrosis, the accumulation of extracellular matrix or scar 
tissue, represents a wound healing response to injury and ultimately can evolve to 
cirrhosis. Patients with cirrhosis, in turn, have increased risk of developing hepatocellular 
carcinoma. Other common clinical manifestations of HH are hypogonadism, 
cardiomyopathy, arthropathy and diabetes (Ganz and Nemeth, 2012; Pietrangelo, 2010). 
According to the clinical outcomes and the genes affected in the disease, HH can be 
divided into HFE-related HH, juvenile hemochromatosis, TfR2-associated 
hemochromatosis and ferroportin-related HH. The molecular mechanism affected in the 
four types is the iron sensing-hepcidin axis (Silva and Faustino, 2015). 
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2.1.1. HFE-related HH 
HFE-HH, also known as classic HH or HH-type I (Silva and Faustino, 2015), is the most 
common genetic disorder in populations of northern European ancestry, with a 
prevalence of 0.5% (Yun and Vincelette, 2015). This mildest form of HH is characterized 
by a gradual deposition of iron in organs with major clinical manifestation in males aged 
40-50 years old and in post-menopausal women (Pietrangelo, 2010). Women are less 
frequently and less severely affected than men, probably because of menstruation 
(Pietrangelo, 2010), which allows the excretion of iron. HFE-HH is an autosomal 
recessive disease that is most frequently associated with the HFE C282Y mutation in 
homozigosity or, more rarely, in heterozigosity with the H63D gene mutation. (Yun and 
Vincelette, 2015). The H63D mutation results in the substitution of aspartic acid for 
histidine at amino acid 63 of the HFE gene. This mutation only causes HH if combined 
with the C282Y mutation (Ayonrinde et al., 2008). The C282Y mutation in HFE, a 
missense mutation, disrupts a disulfide bond that is essential for the β2-microglobulin 
binding. Thus, HFE is not carried to the cell surface and does not interact with TfR1, 
deregulating hepcidin expression (Pietrangelo, 2010). The majority of genetically 
affected individuals are identified because of laboratory abnormalities or family history 
rather than overt disease (Ganz and Nemeth, 2012), since only a small percentage of 
C282Y homozygotes develop HH symptoms (Pietrangelo, 2010; Wood et al., 2012). The 
incomplete penetrance of the disease suggests the existence of modifiers of clinical 
expression, which remain mostly unidentified. While alcohol abuse and male gender are 
known to favor clinical expression, genetic polymorphisms in genes associated with 
fibrogenesis, antioxidant activity and inflammation are also suspected to have a 
significant contribution (Bahram et al., 1999; Pietrangelo, 2010; Wood et al., 2012). 
 
2.1.2. Non-HFE hereditary hemochromatosis 
The remaining forms of HH are clinically more severe than HFE-HH. Juvenile 
Hemochromatosis (JH), also known as HH-type II, is an autosomal recessive disorder 
characterized by mutations in the HJV and HAMP genes (Ayonrinde et al., 2008; Roetto 
et al., 2003). JH presents an early onset of manifestations of iron overload, including 
cardiomyopathies and reproductive defects (Silva and Faustino, 2015), usually by the 
second and third decades of life (Ayonrinde et al., 2008). 
TfR2-associated hemochromatosis (or HH-type III) is an autosomal recessive 
disorder that, as for HFE-HH, manifests from the third or fourth decade of life 
(Pietrangelo, 2010). However, HH-type III is characterized by mutations in the TfR2 gene 
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and patients exhibit even greater variation in the severity of symptoms (Ayonrinde et al., 
2008). 
Ferroportin-related HH, also known as HH-type IV, is an autosomal dominant disease. 
It is associated with mutations in the FPN gene (Silva and Faustino, 2015) and the age 
of clinical onset is in the fourth to fifth decade of life (Pietrangelo, 2005). There are two 
forms of the disease: ferroportin loss of function and ferroportin gain of function. In the 
first case, mutants are unable to export iron from cells, which leads to cellular iron 
overload and low transferrin saturation. On the other hand, in the ferroportin gain of 
function form, cells are able to export iron but are insensible to down-regulation by 
hepcidin. This results in the constant absorption of iron by enterocytes and its constant 
release from cells, resulting in increased Tf saturation and parenchymal iron overload 
(Pietrangelo, 2010; Silva and Faustino, 2015). 
 
3. Oxidative stress 
As previously mentioned, oxidative stress can act as a modifier of the clinical expression 
of HH and it can cause cellular injury in organs that accumulate high amounts of iron, 
such as the liver. The oxidative metabolism is not equal throughout the liver, since the 
acinus, the basic functional unit of the liver, is divided in 3 zones. The hepatic lobule, the 
classical structural unit of the liver (Bioulac-Sage and Lebail B. Balabaud, 2007), has a 
shape of a hexagon, with the portal triads (hepatic artery, bile duct and portal vein) in the 
corners and a central vein in the central structure (LeCluyse et al., 2012). Parenchymal 
cells or hepatocytes radiate from the central vein to the perimeter of the lobule and define 
the acinus, which is demarcated into three discrete zones. Zone 1 is the periportal region, 
zone 2 is the midlobular region and zone 3 is the pericentral region (Rappaport, 1977) 
(Figure 6). Oxygen tension is higher in zone 1, since blood enters the liver from the 
portal veins and hepatic arteries at the portal triads, flows through the sinusoidal 
microvasculature surrounded by the plates of parenchymal cells, and exits from the 
central vein (LeCluyse et al., 2012). 
Iron, in the presence of aerobic respiration byproducts, like H2O2 and O2•-, is capable 
of catalyzing the oxidation of biomolecules. This happens through the formation of the 
hydroxyl radical (HO•), by means of the Fenton and the Haber-Weiss reactions (Halliwell 
and Gutteridge, 1990; Stadtman, 1993): 
 
H2O2+ Fe2+ → Fe3+ + OH– + HO• (Fenton reaction) 
O2•-+ Fe3+ → Fe2+ + O2 
H2O2 + O2•-                 OH– + HO• + O2 (Haber-Weiss reaction) 
Fe3+ 
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Figure 6. Structural and functional zonation of the liver. Adapted from (LeCluyse et al., 2012) 
 
When the cellular concentration of ROS exceeds the capacity of the cell to eliminate 
them, oxidative damage occurs in DNA, RNA, proteins and lipids (Cabiscol et al., 2000; 
Tamarit et al., 1998). Free radicals attack directly polyunsaturated fatty acids in 
membranes and initiate lipid peroxidation, which decreases membrane fluidity and leads 
to the formation of more radicals and other lipid peroxidation byproducts, such as 
malondialdehyde (MDA) (Cabiscol et al., 2000). The modifications caused by ROS are 
deleterious to the cell, since they lead to a loss of function of membranes and proteins 
and block DNA replication or cause mutations (Cabiscol et al., 2000). Hence, organisms 
have developed a set of defense systems to mitigate the damaging effects of ROS 
(Tamarit et al., 1998). 
 
3.1. Antioxidant defense 
Chemically reactive oxygen has to be scavenged, in order to maintain an intracellular 
reducing environment (Cabiscol et al., 2000). Cellular antioxidant system can be divided 
into non-enzymatic and enzymatic. Non-enzymatic antioxidants include NADPH and 
NADH pools, β-carotene, ascorbic acid, α-tocopherol and glutathione (Cabiscol et al., 
2000). As glutathione only contributes to the antioxidant defense in its reduced form 
(GSH), the enzyme glutathione reductase (GR) reduces the oxidized form (GSSG) using 
NADPH as a source of reducing power (Cabiscol et al., 2000). GR is constitutively active 
and inducible upon oxidative stress, so glutathione exists mostly in its reduced form 
(Zitka et al., 2012). The ratio of reduced to oxidized glutathione is a marker of cellular 
toxicity. Under normal conditions, GSH is present in mammalian cells in the 
concentration range of 1-10 mM. In a resting cell, the molar GSH:GSSG ratio exceeds 
100:1, while in various models of oxidative stress, this ratio can decrease to values of 
10:1 and even 1:1 (Chai et al., 1994). Several enzymes are capable of scavenging ROS, 
including: superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase 
(GPx). SOD, the first genuine ROS-metabolizing enzyme discovered (McCord and 
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Fridovich, 1969), dismutates superoxide (O2•-) to hydrogen peroxyde (H2O2) (Nordberg 
and Arner, 2001): 
2O2•- + 2H+ → H2O2 + O2 
CAT, an heme-containing enzyme, catalyses the dismutation of H2O2 formed by SOD 
and other enzymes to water and molecular oxygen (Nordberg and Arner, 2001): 
2 H2O2 → O2 + 2H2O 
GPx is also capable of reducing H2O2, using glutathione as substrate, which liberates 
GSSG (Nordberg and Arner, 2001): 
2GSH + H2O2 → GSSG + 2H2O 
GR is then needed to complete the cycle, reducing GSSG to GSH. 
Peroxiredoxins are enzymes capable of directly reducing peroxides, such as 
hydrogen peroxide and different alkylhydroperoxides, with the use of electrons provided 
by a physiological thiol like thioredoxin (Nordberg and Arner, 2001; Rhee et al., 2005). 
Thioredoxin reductase, homologous to GR, catalyzes the reduction of the redox-active 
disulfide in Trx (oxidized Trx) by NADPH (Zhong et al., 2000). 
 
3.2. NRF2 pathway 
Cells have programs to counteract the stress imposed by oxidants, as mentioned above. 
Under normal circumstances, enzymes involved in the antioxidant response are not 
expressed at their maximal capacity. However, in response to oxidative stress, the 
transcription of these enzymes is enhanced (Kensler et al., 2007). Nuclear factor-
erythroid 2-related factor 2 (NFE2L2/NRF2) is the key transcription factor involved in this 
mechanism. 
Many of the cytoprotective enzymes that take part in the antioxidant response are 
encoded by genes containing antioxidant response elements (ARE). The ARE is a cis-
acting enhancer sequence located in the gene promoter region (Nguyen et al., 2003). 
NRF2 is a basic leucine zipper transcription factor that regulates transcriptional induction 
of ARE-containing genes in response to changes in the cellular redox status, such as 
during increased production of free radical species (Kensler et al., 2007; Lee et al., 
2003). Under normal conditions, NRF2 is mainly localized in the cytoplasm through an 
interaction with Kelch ECH associating protein 1 (KEAP1) and the actin cytoskeleton 
(Kensler et al., 2007). Despite the fact that NRF2 mRNA is constitutively expressed, 
KEAP1 targets NRF2 for polyubiquitination and degradation, resulting in a short protein 
half-life and, consequently, in the low basal expression of the cytoprotective enzymes 
and proteins in quiescent cells under normal physiological conditions (Kensler et al., 
2007). During exposure to electrophiles or oxidative stress, KEAP1 becomes oxidized at 
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critical cysteine residues. As a result, NRF2 escapes KEAP1 control and translocates to 
the nucleus, where it dimerizes with small musculoaponeurotic fibrosarcoma (MAF) 
proteins and promotes the expression of ARE-containing genes (Kansanen et al., 2012; 
Suzuki et al., 2013). The binding to and regulation of NRF2 by KEAP1 have been 
explained by a “hinge and latch model” (Tong et al., 2006), as described in Figure 7. 
 
 
Figure 7. Activation of the KEAP1-NRF2-ARE pathway by oxidants/electrophiles. Under homeostatic conditions, NRF2 
is mainly localized in the cytoplasm through an interaction with KEAP1 and the actin cytoskeleton. KEAP1 is a five-domain 
protein consisting of an N-terminal broad complex, Tramtrack and Bric-à-brac (BTB) domain, an intervening region with 
cysteine (Cys) residues, a C-terminal Kelch domain with double glycine repeats (DGR), and the C-terminal domain. 
KEAP1 homodimerizes at the BTB domain, which is also a binding site for Cullin 3 (Cul3). The KEAP1 homodimer binds 
to a single NRF2 molecule through the ETGE and DLG motifs of NRF2, each binding to a DGR domain in KEAP1. 
According to the proposed hinge and latch model (Tong et al., 2006), ETGE is a high-affinity motif (“hinge”) whereas DLG 
is a low-affinity one (“latch”). KEAP1 functions as an adaptor protein in the Cul3-based E3 ligase complex, which results 
in the polyubiquitination (Ub) of the lysine residues situated between the DLG and ETGE motifs, and subsequent 
proteasomic degradation of NRF2. Under stressed conditions, the modification of critical cysteine residues of KEAP1 
destabilizes its binding to the DLG motif of NRF2, which blocks ubiquitination/proteasomal degradation and allows NRF2 
to escape KEAP1 control and translocate into the nucleus. In the nucleus, NRF2 heterodimerizes with small MAF proteins 
and promotes the expression of ARE-containing genes involved in cell stress response, drug metabolism, detoxification, 
and transport. NRF2 may also be phosphorylated (P) by stress-activated kinases. 
 
3.2.1. NRF2 target genes 
Through the study of NRF2 target genes and pathways in mouse models, NRF2 was 
found to regulate the susceptibility to diseases. Besides, clustering of the NRF2-
dependent upregulated genes in response to stress has revealed pathways involved in 
xenobiotic detoxification and antioxidant response (Kensler et al., 2007). Some of the 
genes upregulated by NRF2 are NAD(P)H:quinone oxireductase 1 (NQO1), heme 
oxygenase 1 (HO-1), glutamate-cysteine ligase (GCL) and glutathione-S-transferases 
(GSTs) (Klaassen and Reisman, 2010). These genes encode antioxidant and detoxifying 
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enzymes that are involved in ROS scavenging and in xenobiotics detoxification, in order 
to diminish cell damage. NRF2 also regulates the expression of transporters involved in 
the drug efflux (Klaassen and Reisman, 2010).  
 
3.2.2. NRF2, a key protector against liver iron toxicity 
NRF2 was recently shown to protect liver cells against iron toxicity in vitro and in vivo. 
Primary hepatocyte cultures from wild-type (WT) mice supplemented with ferric 
ammonium citrate (FAC, a source of inorganic iron that mimics NTBI found in the plasma 
of HH patients) showed increased levels of NRF2 in the nuclei, which was associated 
with the induction of cytoprotective genes (Nqo1, Gclc and Gsta1) in an NRF2-dependent 
manner. Moreover, FAC lead to a dose-dependent reduction in the activity of 
mitochondrial dehydrogenases in Nrf2-/- but not in WT hepatocytes. Authors suggested 
that Nrf2-/- cells are more susceptible to iron-induced oxidative stress than their WT 
counterparts, since iron increased 8-hydroxyguanine DNA glycosylase 1-sensitive sites 
(a marker of oxidatively damaged DNA) exclusively in Nrf2-/- hepatocytes. Likewise, an 
iron-rich diet caused a significant increase in the expression of cytoprotective genes in 
mouse liver in an NRF2-dependent manner. In this model of acute iron overload, Nrf2-/- 
mice displayed elevated activity of the serum transaminases alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) (enzymes released by injured 
hepatocytes), mitochondrial injury and oxidatively damaged DNA. The authors have also 
demonstrated that mito-TEMPOL, an antioxidant targeted to the mitochondria, abrogates 
the hepatotoxicity of dietary iron towards Nrf2-/- animals (Silva-Gomes et al., 2014).  
 
3.2.3. Nrf2 polymorfisms 
The use of Nrf2-/- mouse in model systems has provided insights into the role of NRF2 in 
the pathogenesis of various human disorders. Furthermore, studies have revealed 
strong associations between NRF2 sequence variations and disease risks. Most of the 
phenotype-associated variants are in the promoter region and presumed to be involved 
in NRF2 gene regulation (Cho, 2013). For example, the single nucleotide polymorphisms 
(SNPs) Rs6721961 (C→A) and Rs35652124 (A→G) were found to reduce the 
transcription activity of NRF2 (Cho, 2013), decreasing NRF2-dependent gene 
transcription (Shimoyama et al., 2014). These SNPs are also known to be associated 
with Parkinson’s disease and chronic obstructive pulmonary disease, among others 
(Cho, 2013). 
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4. Aims 
The importance of NRF2 in the protection against hepatic iron toxicity in a model of acute 
iron overload (Nrf2-/- mouse fed an iron-rich diet) was recently demonstrated by the host 
laboratory (Silva-Gomes et al. 2014). This prompted us to study the effect of Nrf2 
suppression in a model of chronic iron overload that mimics human HH, the Hfe-/- mouse. 
The group has generated a double knock-out mouse for Hfe and Nrf2 genes and 
investigated the potential occurrence of spontaneous liver injury in mice of 6-18 months 
of age, when comparing with wild-type and single knock-out animals. Previous results 
from the group revealed that, in the absence of NRF2, the mild hepatic iron overload 
observed in Hfe-/- mouse associated with increased necroinflammation, macrophage iron 
deposits and fibrosis along with ageing. This suggested that the pathology is age-
dependent, which is compatible with the late onset of HH. The main aim of this work is 
to determine whether NRF2 acts as a modifier of the clinical expression of HH. 
 By studying 24 months old Hfe/Nrf2-/- mice, we expect to determine if the lack of 
functional NRF2 signaling prompts the mouse model of HH to develop 
spontaneous fibrosis in aged individuals. 
 We also expect to identify polymorphisms/genotypes in the human NRF2 gene 
promoter that may influence disease penetrance in C282Y+/+ patients. 
This could increase current understanding of the role of NRF2 in the protection against 
hepatic iron toxicity, and help determine the risk of an HH patient developing iron 
overload-related liver disease. 
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Material and Methods 
 
1. Animal study 
1.1. Animals 
Female wild-type (WT) (n=6), Nrf2-/- (Itoh et al., 1997) (n=8) and Hfe-/- mice (Bahram et 
al., 1999) (n=6) on a C57BL/6J background, and Nrf2/Hfe-/- mice generated by the group 
(n=7) were housed and bred at the ’Instituto de Biologia Molecular e Celular’ animal 
facility until the age of 24 months. Mice were fed standard rodent chow (Mucedola 
4RF21-GLP containing 480 mg/kg iron) ad libitum and were overnight fasted before 
sacrifice. Animals were anesthetized with isofluorane (B. Braun, Portugal) and blood was 
collected by retro-orbital bleeding. After performing cervical dislocation, mice were 
dissected for organ collection: tail, liver, spleen, pancreas and kidneys. Tissues were 
snap-frozen in liquid nitrogen and stored at -80 °C for subsequent RNA extraction and 
quantification of non-heme iron. Body, spleen and liver weight were determined. 
The entire experiment was carried out in compliance with the recommendations of the 
European Convention for the Protection of Vertebrate Animals used for Experimental 
and Other Scientific Purposes (ETS 123) and 86/609/EEC Directive and Portuguese 
rules (DL 129/92). The animal experimental protocol was approved by ’Direção Geral de 
Alimentação Veterinária‘ and by the Institute’s ethical committee. All researchers 
involved in animal processing attended a FELASA B course and the work was overseen 
by a researcher with FELASA C accreditation. 
 
1.2. Hematological measurements 
Blood was diluted 1:1 with 1,5% (v/v) K3-ethylenediamine tetraacetic acid (K3EDTA). 
Hemoglobin, red blood cell counts, hematocrit, mean corpuscular volume, mean 
corpuscular hemoglobin and the percentage of reticulocytes were assessed on a 
Coulter-S counter (Coulter Electronics, Fullerton, CA) , at a certified laboratory (Corelab, 
’Centro Hospitalar do Porto’, CHP, Portugal). 
 
1.3. Serum analysis 
Blood was allowed to sit for 30 min at room temperature (RT) and centrifuged at 10 000 
×g, for 10 min for serum collection. Alanine aminotransferase (ALT) activity, glucose, 
triglycerides and iron concentration, and the total iron-binding capacity (TIBC) were 
assessed on a Cobas C8000 analyzer (Roche Diagnostics, Mannheim, Germany) at the 
CHP Corelab. Transferrin saturation was calculated by dividing serum iron concentration 
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by TIBC. Serum insulin and erythropoietin (EPO) concentrations were measured using 
a mouse enzyme-linked immunosorbent assay (ELISA) kit (Mercodia, Sweden) and a 
commercially available rodent Quantikine Epo Immunoassay Kit (R&D Systems, USA), 
respectively. The lactate dehydrogenase activity in the serum was determined using a 
LDH colorimetric assay kit (Sigma-Aldrich, Germany) according to the manufacturer's 
protocol. The serum levels of a panel of cytokines/chemokines (GM-CSF, IFNγ, IL-1B, 
IL-6, IL-10, MCP-1 and TNFα) were determined with a multi-analyte detection system 
(Milliplex Map Kit – Mouse Cytokine/Chemokine Magnetic Bead Panel, Millipore, 
Germany), according to the manufacturer’s instructions. Detection was performed with 
the xPonent software in the Luminex 200 (Luminex Corporation, USA), and data were 
analyzed through the MILLIPLEX Analyst software. 
 
1.4. RNA extraction and cDNA synthesis 
To isolate the total RNA from liver, spleen and kidneys, 1 mL of TRI Reagent® (Sigma-
Aldrich, Germany) was added to 50-100 mg of tissue. Samples were homogenized and 
left at RT for 5 min. Samples were then centrifuged at 12 000 ×g for 10 min at 4°C and 
the cleared supernatant was transferred to a new tube. After an incubation of 5 min at 
RT, 200 μL of chloroform were added to the supernatant. The tubes were vigorously 
shaken by hand for 15 s, incubated at RT for 2-3 min and centrifuged at 12 000 ×g for 
15 min at 4°C. The aqueous phase was transferred to a new tube and 500 μL of 100% 
(v/v) isopropanol were added. Tubes were homogenized by inversion and incubated at 
RT for 10 min. After a centrifugation at 12 000 ×g for 10 min at 4ºC, the supernatant was 
removed. The pellet was washed with 1 mL of 75% (v/v) ethanol and the tubes were 
vortexed and centrifuged at 7 500 ×g for 5 min at 4°C. The supernatant was removed 
and the pellet was air dried for 5-10 min. The RNA pellet was ressuspended in RNase-
free water (Sigma-Aldrich, Germany) and incubated in a heat block at 55-60ºC for 10-15 
min. RNA concentration was measured at 260 nm by a NanoDrop spectrophotometer 
(ThermoScientific, USA) and RNA integrity was assessed by capillary electrophoresis in 
Experion (Bio-Rad Laboratories, USA). 
Extracted RNA was treated with DNase (Turbo DNA-free™ kit, Ambion, Life 
Technologies, USA), in order to remove contaminating genomic DNA. To a final quantity 
of 4 μg of RNA, 2.5 μL of 10× TURBO DNase Buffer and 1 μL of TURBO DNase were 
added. RNase free water was added up to a final volume of 25 μL. Samples were 
incubated at 37°C for 30 min and 2.5 μL of DNase Inactivation Reagent were added. 
After an incubation of 2 min at RT, samples were centrifuged at 10 000 ×g for 1.5 min 
and the RNA was transferred to a new tube. 
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First-strand cDNA was synthesized with the ThermoScript RT-PCR system 
(Invitrogen, Life Technologies, USA). 1 μL of Primer Oligo (dT) and 2 μL of dNTP mix 
were added to 9 μL of DNAse treated RNA. Samples were incubated at 65°C for 5 min 
and were posteriorly placed on ice. 4 μL of 5× cDNA Synthesis Buffer, 1 μL of 
dithiothreitol (DTT) 0,1 M, 1 μL of RNaseOUT, 1 μL of diethylpyrocarbonate (DEPC)-
treated water and 1 μL of ThermoScript RT were added. Samples were incubated at 
55°C for 60 min and then at 85°C for 5 min. 1 μL of RNase H was added and samples 
were incubated at 37°C for 20 min. Samples were diluted (1:2) with DEPC-treated water. 
 
1.5. Real-time reverse-transcription (RT)-PCR 
The relative transcription levels of selected genes in a target cDNA sample were 
determined by real-time polymerase chain reaction (qPCR) with the primers (STABvida, 
Portugal) listed in Table 1. PCR reactions were performed in duplicate and in a total 
volume of 20 μl. To each reaction, 10 μL of iQ SYBR Green Supermix (Bio-Rad 
Laboratories, USA), 0.08 μL of each primer from a stock solution at 50 μM, 8.84 μL of 
RNase free water and 1 μL of cDNA were added. PCR was performed in the iQ5 Real-
Time PCR system (Bio-Rad) with the following amplification conditions: denaturation at 
95°C for 4 min and 40 cycles of 94°C for 30 s, annealing at 59-61°C for 45 s, and 
extension at 72°C for 30 s. A standard curve, based on a serial dilution (1, 1:10 and 
1:100) of a previously prepared liver cDNA pool, was performed for each gene. The 
quantity of each transcript was estimated against the respective standard curve and 
normalized against the quantity of the endogenous control gene hypoxanthine 
phosphoribosyltransferase (Hprt). The specificity of the PCR reaction and the absence 
of primer dimers were confirmed by melting curve analysis.  
 
1.6. Quantification of non-heme iron 
Non-heme iron in liver, spleen and kidney tissues stored at -80°C was measured by the 
bathophenanthroline method (Torrence and Bothwell, 1980). Tissue samples weighting 
approximately 100 mg were dried in a microwave oven (MDS 2000, CEM), in iron-free 
Teflon vessels (ACV-Advanced Composite Vessel; CEM, Mathews, NC). After 
determining dry tissue weights, samples were digested in 1 mL of acidic mixture [0.1 
g/mL hydrochloric acid and 822 μL/mL trichloroacetic acid 37% (v/v)] for 20 h at 65°C. 
1mL of chromogen reagent [5 volumes of deionized water, 5 volumes of saturated 
sodium acetate and 1 volume of 0.1% (w/v) bathophenanthroline sulfonate and 1% (v/v) 
thioglycolic acid] and 275 or 250 μL of deonised water were added to 25 (liver) or 50 μL 
(spleen and kidney) of the supernatant obtained in the digestion reaction. The standard 
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solution was prepared with 1 mL of chromogen reagent, 150 μL of deonised water and 
150 μL of a stock iron standard solution [22.3 mg carbonyl iron powder, 1096 μL 
hydrochloric acid 36.5% (v/v) and deonised water to a final volume of 20 mL]. A colored 
product was obtained and the absorbance was measured spectrophotometrically at 535 
nm with a μQuant equipment (BioTek, Germany). 
 
Table 1. Sequences of the oligonucleotide primers used in qRT-PCR and the respective annealing temperatures. 
Gene 
Primer Forward 
(5’ → 3’) 
Primer Reverse 
(5’ → 3’) 
Ta 
(ºC) 
Hprta AGATGGGAGGCCATCACATTGT ATGTCCCCCGTTGACTGATCAT 59 
Hampb CATGTTCCAGAGGCGAAGGAGG GCAGCACATCCCACACTTTGATC 59 
Acta2c ACCCAGCACCATGAAGATCAAG AGGTAGACAGCGAAGCCAGGA 59 
Nqo1c GTGCAGAAGCGAGCTGGAAATACTC CGAATCTTGATGGAGGACTGGATGC 59 
Col1ac TCCTGGCAACAAAGGAGACAC GGGCTCCTCGTTTTCCTTCT 59 
Timp1c CATCTGGCATCCTCTTGTTGCT AAGGTGGTCTCGTTGATTTCTGG 59 
Ccl2c ATGATCCCAATGAGTAGGCTGGAG GACCTCTCTCTTGAGCTTGGTGAC 59 
Tnf-αc CTGTAGCCCACGTCGTAGCA CGGCAGAGAGGAGGTTGACT 59 
Il-6d CTGCAAGAGACTTCCATCCAG AGTGGTATAGACAGGTCTGTTGG 60 
Spicc AAAGGGAGGAAGAGGCAGGAG CCCAGAGTTCAGCGAGTGTTTC 59 
G6pcc CAATCTCCTCTGGGTGGCAGT GCTGTTGCTGTAGTAGTCGGTGTCC 59 
Pepckc ATGCGACCCTTCTTCGGCTAC GAACTTGCCATCTTTGTCCTTCC 59 
Hmox1c GAAGGGTCAGGTGTCCAGAGAAGG CGCTCTATCTCCTCTTCCAGGGC 61 
F4/80e CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 59 
Epoc AATTCCTCCCAGCCACCAGAGA AGACCCGGAAGAGCTTGCAGAA 59 
a. (Silva-Gomes et al., 2014); b. (Ilyin et al., 2003); c. Designed with Primer 3 software (Rozen and Skaletsky, 2000); d. 
Kindly supplied by Tânia Cruz; e. (Wan et al., 2014); Ta = annealing temperature. 
 
1.7. Histological analysis 
Liver, spleen, pancreas, kidney and heart samples were fixed with 10% formalin for 24 
h, dehydrated and embedded in paraffin. Three micrometer-thick sections of each organ 
were obtained and dried overnight at 37°C. Prior to each staining, sections were 
immersed twice in xylene for 10 min at room temperature, passed through descending 
concentrations of ethanol [100% (v/v), 96% (v/v), 70% (v/v) and 50% (v/v), each 5 min] 
and washed three times in distilled water for 5 min each. After the coloration, sections 
were dehydrated in ascending concentrations of ethanol and cleared in xylene for 10 
min. Sections were covered with Entellan mounting medium (Merck, Germany) and a 
glass cover slip. Microscope slides were observed on a Light Microscope Olympus CX31 
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and photos were captured with a DP-25 Camera (Imaging Software Cell^B). All slides 
were examined by the same observer, in a blind manner (i.e. with no previous knowledge 
of the animals' genotypes). 
 
1.7.1. Hematoxylin and eosin staining 
Standard hematoxylin and eosin staining (H&E) was applied to all tissues to make a 
histopathological assessment of the preparations. Hydrated sections were immersed in 
Gill’s Hematoxylin (Merck, Germany), rinsed in tap water and immersed in eosin (Merck, 
Germany) for 5 min each. Finally, sections were rinsed in tap water for 30 s. Liver 
sections were graded according to steatosis, inflammation and necrosis. Steatosis was 
graded as absent (<5%), light (5%–33%), moderate (>33%–66%), or severe (>66%) 
according to the amount of parenchyma affected. The assessment of steatosis grading 
was made at low magnification (4× and 10× objectives) and it considered only the portion 
of the liver section occupied by the hepatocytes (ignoring large bands of fibrosis, portal 
areas, vein profiles, etc.). The zonal distribution of steatosis was categorized into four 
patterns: zone 3 predominant, zone 1 predominant, pan-acinar or azonal (Chalasani et 
al., 2008). Lobular inflammation was divided into four categories, according to the 
number of visible foci at 10× objective: no foci, <4 foci, 4-8 foci, >8 per 100× field (Kleiner 
et al., 2005). Necrosis was graded as absent, spotty necrosis (one or a few necrotic 
hepatocytes), confluent necrosis and bridging necrosis. 
 
1.7.2. Sirius red staining 
Sirius red staining was applied to the liver sections, in order to evaluate the fibrotic area. 
Nuclei were stained with Mayer’s hematoxylin (Sigma-Aldrich, Germany) for 8 min and 
sections were washed under running tap water for 5 min. Sections were then stained 
with a 0.1% (v/v) solution of Sirius red F3BA [Direct Red 80 (Sigma-Aldrich, Germany) 
in saturated aqueous solution of picric acid] for one hour at RT and rinsed two times in a 
0.5% (v/v) HCl solution. 
Fibrosis was graded as none (0), mild/moderate in zone 3, portal/periportal only (1), 
portal/periportal and perisinusoidal (2) bridging fibrosis (3) and cirrhosis (4) (Kleiner et 
al., 2005). The fibrotic area was then evaluated with a light microscope fitted with a 
polarisation filter, which renders the staining specific for type I collagen. Three random 
microscope fields of the liver, excluding regions of the capsule and the large portal tracts, 
were captured at 100× magnification and saved as .TIF files. Images were then analyzed 
using ImageJ software. Red Green Blue (RGB) stack type was selected and upper and 
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lower thresholds were defined to avoid pixel saturation. These remained unaltered during 
the measurement of the percentage of fibrotic area in a whole batch of images. 
 
1.7.3. Perls’ Prussian Blue staining 
The presence of iron deposits in the different organs was assessed by Perls’ Prussian 
Blue staining. Sections were stained with Perls solution [equal parts of 2% (w/v) 
potassium ferrocyanide and 2% (v/v) hydrochloric acid 37% (v/v)] for 30 min and washed 
in several changes of distilled water for 5 min. The sections were counterstained with 
Neutral Red [1 g Neutral Red (Sigma-Aldrich, Germany), 100 mL distilled water and 1 
mL glacial acetic acid] for 1 min and rinsed in distilled water. Siderosis was graded 
according to the size of iron deposits, as well as their cellular and lobular location. 
Grading consisted in three scores: hepatocytic (ranging 0-36), sinusoidal (ranging 0-12) 
and portal (ranging 0-12). Hepatocytic iron was graded as 0 (absence of iron), 3 (faint 
staining), 6 (nonconfluent granules), 9 (confluent deposits) or 12 (large masses) 
according to granules size in each Rappaport area. Sinusoidal iron was graded as 0 
(absence of iron), 1 (faint staining), 2 (small granules), 3 (large deposits) or 4 (clusters 
of overload cells) according to granules size in each Rappaport area. Portal iron was 
graded as 0 (absence of iron), 1 (deposits in < 1/3 of the portal tracts), 2 (deposits in 1/3 
of the portal tracts), 3 (deposits in 2/3 of the portal tracts) or 4 (deposits in all portal tracts) 
according to the percentage of iron overloaded macrophages, biliary cells and vascular 
walls (Deugnier et al., 1993). 
 
1.7.4. TUNEL assay 
DNA fragmentation resulting from apoptotic cell death was determined by Terminal 
deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay. Following 
dehydration, liver sections were washed in phosphate buffered saline (PBS) for 5 min. 
Sections were then incubated with proteinase K (20 μg/mL) in Tris-HCl 10mM for 20 min 
at 37ºC and for 10 min at RT and washed 2 times in PBS 1×. Microscope slides were 
incubated with the TUNEL reagents (50 μL Enzyme Solution and 450 μL Label solution) 
of the In Situ Death Detection Kit, Fluorescein (Roche Diagnostics, Germany) for 1 h at 
37ºC. Sections were then washed 3 times in PBS 1×. Finally, sections were incubated 
with 0,2 μg/mL 4',6-diamidino-2-phenylindole (DAPI) in the dark for 15 min at RT. The 
microscope slides were mounted with Vectacshield (Vector Laboratories, USA) and 
sealed with nail polish. Ten random microscope fields of each liver were obtained with a 
40× objective and the number of TUNEL-positive cells was counted. As a positive 
control, liver sections were treated with DNase. 
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1.8. Evaluation of oxidative stress  
To evaluate oxidative stress parameters in the liver, a small portion of this organ was 
homogenized in a homogenizing solution [0.85 g KH2PO4 25 mM, 2.67 g Na2HPO4.2H2O 
30 mM, 0.25 mL Triton X-100 0,1% (v/v) to a final volume of 250 mL, pH 7,0] in the 
proportion of 2 mL of solution per gram of fresh weight. Total protein was quantified with 
the DCTM Protein Assay (Bio-Rad, USA) as per the manufacturer’s instructions and the 
homogenate was used for the following assays. 
 
1.8.1. Thiobarbituric Acid Reactive Substances (TBARS) assay 
100 μL of the homogenate were diluted with 200 μL of 10% (v/v) trichloroacetic acid 
(TCA). The dilution was vortexed and centrifuged at 6 000 rpm for 1 min at 4ºC. 200 μL 
of the diluted homogenate were incubated with 200 μL of 1% (w/v) thiobarbituric acid in 
a water bath at 95ºC for 40 min. After cooling down, the absorbance at 535 nm was 
measured in a spectrophotometer. The malondialdehyde (MDA) standard curve was 
calculated against previously determined values (Professor Maria João Martins, 
personal communication).  
 
1.8.2. Quantification of the GSH/GSSG ratio 
The homogenate obtained in 1.8. was centrifuged at 13 000 rpm for 10 min at 4ºC. The 
supernatant was diluted with an equal part of 10% (v/v) perchloric acid (PCA) and 
centrifuged at 13 000 rpm for 2 min at 4ºC. 20 μL of the supernatant were utilized to 
quantify the total glutathione (GSX) and 200 μL to quantify the oxidized form (GSSG). 
The reduced form (GSH) was calculated as follows: 
GSH = GSX – 2 × GSSG 
 
1.8.2.1. Quantification of the total gluthatione 
20 μL of the supernatant obtained in 1.8.2. were diluted 10 times with 5% (v/v) PCA in 
phosphate solution (10.2 g of Na2HPO4.2H2O 57.3 mM, 11.2 g of NaH2PO4.H2O 81.2 
mM and 0.23 g dissodic EDTA 0.62 mM to a final volume of 1 L, pH 7,5). 200 μL of 
KHCO3 0.076 M were added and the tubes were vortexed and centrifuged at 13 000 rpm 
for 1 min at 4ºC. 100 μL of the supernatant were transferred into a 96-well plate in 
triplicate and 65 μL of the reagent solution (3.42 mg of NADPH 3.36 mM, 4.68 mg of 
DTNB 20 mM to a final volume of 3 mL in phosphate solution) were added. The plate 
was incubated for 15 min at 30ºC, protected from light. 40 μL of the glutathione reductase 
solution (10 units per mL of phosphate solution) were added and the absorbance at 405 
nm was measured for 3 min. The trendline equation was defined. 
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1.8.2.2. Quantification of GSSG 
200 μL of the supernatant obtained in 1.8.2. were incubated with 10 μL of 2-vinylpyridine 
for 1 h at 4ºC with agitation. After adding 200 μL of 0.076 M KHCO3, samples were 
vortexed and centrifuged at 13 000 rpm for 1 min at 4ºC. 100 μL of the supernatant were 
added into a 96-well plate and 65 μL of the reagent solution were added. The plate was 
incubated for 15 min at 30ºC, protected from light. 40 μL of the glutathione reductase 
solution were added and the absorbance at 405 nm was measured for 3 min. The 
trendline equation was defined. 
 
1.9. Hydroxyproline Assay 
Liver tissue (10 mg) was homogenized in 100 μL of distilled water. Protein quantification 
was performed with the DCTM Protein Assay Kit (Bio-Rad, USA). The quantity of 
hydroxyproline was determined with the Hydroxyproline Assay Kit (Sigma-Aldrich, 
Germany) following the manufacturer’s instructions. 
 
2. Human study  
2.1. Patients 
The human study was performed with stored DNA samples from Hereditary 
Hemochromatosis (HH) patients who had been referred to the CGPP laboratory Biobank 
for diagnosis. Samples were selected by the following criteria: 1) confirmed 
homozygosity for the HFE C282Y mutation; 2) a written informed consent from the 
patients allowing the use of their DNA samples for research purposes; 3) available stored 
DNA in good quality and sufficient quantity for the purpose of the study. From the 106 
samples fulfilling these criteria, 67 were from patients referred from the HH clinics at the 
Hematology Service, Centro Hospitalar do Porto (CHP), and regularly followed up by Dr. 
Graça Porto, the clinician in charge at the HH clinic, and co-supervisor of this project. 
The availability of complete clinical information from this group of patients allowed us to 
use it for the clinical correlations study, after excluding putative confounding variables 
(see below in statistical analysis). The remaining 39 DNA samples were from patients 
referred for diagnosis by other external services and no complete clinical information was 
available, reason why they were not included in the clinical correlations study. Retrieved 
clinical data were anonymized and confidentiality was maintained during the whole 
analytical process according to Helsinki Declaration and Portuguese Law. The study 
received ethical approval by the CHP Ethics committee. 
The general characteristics and the clinical manifestations of the 67 patients selected 
for the clinical correlation study are presented in Table 2. 
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Table 2. Patients’ general characteristics and frequency of clinical manifestations. 
 
Males Females Total 
n 42 25 67 
Age 43 ± 12 46 ± 11.3 44 ± 12 
    
Ferritin (ng/mL) 2201 ± 1795 902 ± 893 1716 ± 1641 
    
TfSat (%) 82 ± 20 79 ± 16.2 80.5 ± 18.4 
    
TBIS (g) 7.3 ± 4.8a 4.5 ± 3.4b 6.4 ± 4.5c 
    
Mode of presentation 
21/21 17/8 38/29 
(clinical diagnosis/family screening) 
    
HCV+ 1/42 (2.4%) 0/25 1/67 (1.5%) 
    
Related individuals 5/42 (11.9%) 4/25 (16%) 9/67 (13.4%) 
Frequency of clinical manifestation    
Skin pigmentation 8/42 (19%) 4/25 (16%) 12/67 (17.9%) 
    
Diabetes 3/42 (7.1%) 0/25 3/67 (4.5%) 
    
Hypoganadism 1/42 (2.4%) 0/25 1/67 (1.5%) 
    
Arthropathy 5/42 (11.9%) 6/25 (24%) 11/67 (16.4%) 
    
Chirrosis 9/42 (21.4%) 3/25 (12%) 12/67 (17.9%) 
    
Mean ± standard deviation. TfSat (%): transferrin saturation. TBIS: total body iron stores. HCV+: Hepatitis C virus positive. 
aavailable in 31 only; bavailable in 14 only; cavailable in 45 only. 
 
2.2. NRF2 genotyping 
Genotyping of known SNPs of the promoter region of the transcription factor NRF2 was 
performed by PCR amplification of a fragment of 284 bp using the forward primer 5’-
GCG TGG TGG CTG CGC TTT-3’ and the reverse primer 5’-CCG TGC CAC TGC CAA 
CTG C-3’ (STABVida, Portugal). The PCR reaction consisted of 10 μL: 5 μL of master 
mix HotStarTaq Plus DNA Polymerase (Type-it® Microsatellite PCR Kit, Qiagen, 
Germany), 0.5 μL of primer forward 10 μM, 0.5 μL of primer reverse 10 μM and 1 μL of 
DNA in a concentration of 50 ng/μL. The amplification conditions were as follows: 
denaturation at 95°C for 5 min and 40 cycles of 95°C for 30 s, annealing at 63°C for 30 
s, and extension at 72°C for 30 s with a final extension at 60ºC for 30 min. 
The PCR fragment was genotyped at the CGPP laboratory by capillary 
electrophoresis (Sanger sequencing). The total sequencing reaction consisted of 8 μL: 
2 μL of BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, USA), 0.5 
μL of 10 μM forward primer, 2.5 μL of purified PCR product and 3 μL of distilled water. 
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The amplification conditions were as follows: denaturation at 95°C for 5 min and 35 
cycles of 96°C for 10 s, annealing at 50°C for 5 s, and extension at 60°C for 4 min. 
Samples were injected in the ABI 3130xl Genetic Analyzer (Applied Biosystems, USA) 
and the final product was precipitated in DyeEx 96 well plates (Qiagen, Germany). After 
sequencing the fragment, the Rs35652124, Rs670664, Rs150648896 and Rs6721961 
SNPs in the NRF2 promoter region were determined using the ProSeq3 software. 
 
2.3. Datafile collection 
For the purpose of statistical analysis, a datafile was created including, besides the 
genetic information obtained, the following patients’ clinical information: gender and age 
at diagnosis, the systemic iron parameters serum ferritin, transferrin saturation; 
hematological parameters including the numbers of CD8+ T lymphocytes; the total body 
iron stores (TBIS) and/or hepatic iron concentration (HIC) assessed trough a liver biopsy 
or magnetic resonance imaging. The severity of the iron overload was graded according 
to the levels of TBIS (or HIC): >2 g (or >300µmol/g of HIC) corresponding to grade 1 
(light overload), 2-4 g to grade 2 (moderate) and >4 g to grade 3 (severe). The presence 
or absence of the other clinical manifestations, such as skin pigmentation, diabetes, 
cirrhosis, hypogonadism and arthropathy was also registered. 
 
3. Statistical analysis 
3.1. Animal study 
Results are presented as the mean and standard deviation. Unless stated otherwise, 
differences among multiple groups were compared by one-way analysis of variance 
(ANOVA) with Tukey's multiple comparison test using GraphPad Prism version 6.0 for 
Windows (GraphPad Software, California USA). The results were considered statistically 
significant when p<0.05. 
 
3.2. Human study 
Gene allele or genotype frequencies were estimated in unrelated individuals only (n = 
97). For analyses of genotype/phenotype correlations we first selected the 67 patients 
regularly followed up at HH clinics at CHP and in whom complete clinical information was 
available. Further exclusion criteria included: viral infection, such as hepatitis and human 
immunodeficiency virus (HIV), auto-immune disease and alcoholic liver disease (n = 57). 
Given the small sample size, group analysis were restricted to some of the most frequent 
clinical manifestations of HH, namely cirrhosis, arthropathy, or symptomatic patients, 
who presented with clinical evidence of at least one of the following disease 
FCUP 
NRF2 protection against liver injury in human and mouse models of HH 
29 
 
 
manifestations: skin pigmentation, diabetes, hypogonadism, arthropathy, cirrhosis, 
and/or documented severe iron overload (serum ferritin > 2000 and TBIS > 5 g). For the 
purpose of analyzing the impact of particular genotypes on the clinical expression, 
namely on the frequency of liver cirrhosis, more strict clinical criteria were used. Given 
the low probability of clinical expression in asymptomatic, early diagnosed, females or 
young males (<30 years of age), these subjects were excluded from analysis. In addition, 
patients with severe iron overload but in whom a liver biopsy was not available (and thus 
the presence of cirrhosis could not be excluded) were also excluded (n = 36). 
Quantitative results are presented as the mean and standard deviation. In order to fit 
into a normal distribution, serum ferritin values were logarithmic transformed. Differences 
between groups were compared by the Student´s t-test. The Chi-square test was applied 
to test the differences in allele and genotype frequencies. Data were analyzed using 
GraphPad Prism version 6.0 for Windows (GraphPad Software, California USA) and 
statistical significance accepted at p≤0.05. 
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Results 
 
Animal study 
1. Body, liver and spleen weights 
The body weight of each animal was determined prior to sacrifice. Nrf2/Hfe-/- mice 
presented significantly decreased body weight compared to WT (p<0.05) and Hfe-/- 
(p<0.0001) mice (Figure 8.A). Spleen and liver weights were also registered and their 
relative weights were calculated by dividing organ weight by body weight. No significant 
differences in relative liver and spleen weights were found (Figure 8.B and 8.C). 
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Figure 8. (A) Body weight and (B) percentage of relative liver and (C) spleen weights of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- 
mice. 
 
2. Hematological parameters 
The number of red blood cells (RBC) was significantly lower in Nrf2/Hfe-/- mice when 
compared to WT (p<0.001), Nrf2-/- (p<0.01) and Hfe-/- (p<0.0001) mice. Hemoglobin (Hb) 
was also significantly lower in Nrf2/Hfe-/- mice when compared to WT, Nrf2-/- (p<0.05) 
and Hfe-/- (p<0.0001) mice. Nrf2/Hfe-/- mice also presented a significantly decreased 
hematocrit (HCT) when compared to Nrf2-/- (p<0.05) and Hfe-/- (p<0.0001) mice (Table 
3). These data reveal that Nrf2/Hfe-/- mice were mildly anemic. This is in contrast with 
A. B. 
C. 
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Hfe-/- mice, which exhibited significantly higher levels of Hb and HCT when compared to 
their WT counterparts (p<0.05) (Table 3). 
In Nrf2-/- and Nrf2/Hfe-/- mice, the mean corpuscular volume (MCV) was significantly 
increased when compared to WT mice (p<0.05 and p<0.001, respectively. The mean 
corpuscular hemoglobin (MCH) was significantly increased in Nrf2/Hfe-/- mice when 
compared to WT (p<0.0001) and to Nrf2-/- (p<0.001) mice. Hfe-/- mice also showed a 
significantly higher MCH than WT (p<0.001) mice (Table 3). Overall, the data suggest 
that the anemia of Nrf2/Hfe-/- mice is macrocytic and normochromic. 
Reticulocytes are the earliest erythrocytes released into the bloodstream. Because 
they have a shorter life span (1 or 2 days) in the circulation compared to mature RBC 
(120 days), the reticulocyte parameters are reliable tools to evaluate the bone marrow 
erythroid activity (Velasco-Rodriguez et al., 2015). Results revealed a trend for increased 
percentage of reticulocytes in Nrf2/Hfe-/- mice (Table 3). This indicates that the bone 
marrow was responding to the anemia, which suggests that the anemia of Nrf2/Hfe-/- 
mice is regenerative. 
 
Table 3. Hematological parameters of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. 
  WT Nrf2-/- Hfe-/- Nrf2/Hfe-/- 
N 6 8 6 7 
RBC (x106/μL) 8.9 ± 0.6 8.5 ± 0.7 9.3 ± 0.2 7.1 ± 0.8a,b,c 
Hb (g/dL) 13.3 ± 0.9 13.1 ± 0.9 15.1 ± 0.4d 11.6 ± 1.3c,d,e 
HCT (%) 43.2 ± 3.1 44.6 ± 2.8 49.0 ± 2.1d 39.3 ± 3.6c,e 
MCV (fL) 48.4 ± 1.6 52.8 ± 3.6d 52.6 ± 1.2 56.0 ± 3.2a 
MCH (pg) 15.0 ± 0.5 15.5 ± 0.5 16.2 ± 0.1a 16.4 ± 0.4f,g 
N 3 4 2 3 
Reticulocytes (%) 3.7 ± 0.7 5.5 ± 1.9 4.6 ± 0.0 11.7 ± 8.9 
Mean ± standard deviation. ap<0.001 vs. WT; bp<0.01 vs. Nrf2-/-; cp<0.0001 vs. Hfe-/-; dp<0.05 vs. WT; ep<0.05 vs. Nrf2-/-; 
fp<0.0001 vs. WT; gp<0.001 vs. Nrf2-/-. 
 
3. Characterization of the anemia of Nrf2/Hfe-/- mice 
To discover the possible cause of the anemia, several parameters were measured. 
Erythropoietin is a glycoprotein, produced by the kidney, essential for RBC production 
(Chateauvieux et al., 2011). We noted a trend for augmented transcript levels of Epo 
gene in the kidney and EPO levels in the serum of Nrf2/Hfe-/- mice (Figure 9.A and 9.B). 
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On the other hand, serum lactate dehydrogenase (LDH) activity, a clinical marker of RBC 
hemolysis (Kato et al., 2006), was not altered in any of the four genotypes (Figure 9.C). 
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Figure 9. EPO levels and LDH activity in WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. (A) Transcript levels of Epo gene were 
measured in the kidney. (B) Levels of EPO and (C) LDH activity were measured in the serum. 
 
In adult mice, erythropoiesis occurs in bone marrow and splenic red pulp (Sadahira 
and Mori, 1999). Macrophages have been postulated to function as nursing cells for the 
development and differentiation of erythroid cells (Bernard, 1991), so we decided to 
determine the transcription levels of Spic and F4/80 genes in the spleen. Steady-state 
levels of F4/80, a cell-surface antigen expressed in tissue macrophages (Austyn and 
Gordon, 1981), were augmented in Nrf2-/- mice when compared to WT and Nrf2/Hfe-/- 
mice (p<0.05) (Figure 10.A). Spic, which controls the development of red pulp 
macrophages, a splenic subset that removes senescent red blood cells (Gordon and 
Taylor, 2005), did not show statistically significant differences in its transcript levels in 
the spleen (Figure 10.B). The transcript level of Spic was also assessed in the liver. 
Accordingly, no significant differences were detected (Figure 10.C). Macrophages 
destroy aged or damaged red blood cells, but they need HO-1 to detoxify the heme 
released from the breakdown of the engulfed erythrocytes (Kovtunovych et al., 2010). 
Besides, Hmox1 gene dosage has been implicated in the response of the hematopoietic 
system to stress (Fraser et al., 2011). We determined the transcript levels of Hmox1 
A. B. 
C. 
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gene in the liver and spleen and found no statistically significant difference (Figure 10.D 
and 10.E). 
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Figure 10. Expression of macrophages-associated genes in liver and spleen of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. (A) 
Transcript levels of F4/80 gene were measured in the spleen. (B) Transcript levels of Spic gene were measured in the 
spleen and (C) liver. (D) Transcript levels of Hmox1 gene were measured in the spleen and (E) liver.  
 
Since the mice employed in the present study were old (24 months of age), we 
considered important to investigate the possibility of an anemia of inflammation, which 
is why we evaluated a panel of proinflammatory cytokines/chemokines in the mouse 
serum. The levels of five cytokines (GM-CSF, IL-1b, IL-6, IL-10 and TNF-α) and one 
chemokine (MCP-1) exhibited no statistically significant difference between the four 
genotypes. However, IFN-γ was significantly augmented in Nrf2-/- mice in comparison to 
WT mice. (Table 4). 
A. B. 
E. 
D. C. 
FCUP 
NRF2 protection against liver injury in human and mouse models of HH 
35 
 
 
 
 
Table 4. Levels of cytokines and chemokines in the serum of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. 
 WT Nrf2-/- Hfe-/- Nrf2/Hfe-/- 
A
n
a
ly
te
 (
p
g
/m
L
) 
N 6 8 5 7 
GM-CSF 0 ± 0 164.0 ± 213.2 142.9 ± 198.6 137.9 ± 263.3 
IFN-γ 0 ± 0 154.1 ± 252.4* 78.3 ± 108.1 69.19 ± 109.6 
IL-1b 6.0 ± 12.2 429.0 ± 802.0 10.7 ± 12.9 130.7 ± 343.0 
IL-6 23.4 ± 27.3 59.3 ± 68.9 15.2 ± 13.0 57.3 ± 55.4 
IL-10 0.4 ± 0.6 94.0 ± 164.7 6.6 ± 10.5 25.5 ± 52.4 
MCP-1 70.4 ± 46.0 396.5 ± 718.1 41.5 ± 38.9 200.5 ± 465.2 
TNFα 4.7 ± 3.5 44.3 ± 86.4 2.6 ± 2.6 25.1 ± 56.7 
Mean ± standard deviation. *p=0.0359 vs. WT (non-parametric Kruskal-Wallis test with Dunn’s multiple comparisons test) 
 
4. Serum analysis 
Serum analysis revealed that Nrf2/Hfe-/- mice were hypoglycemic, as they presented a 
significantly lower quantity of glucose in the serum at starvation compared to Nrf2-/- 
(p<0.05) and Hfe-/- (p<0.01) mice. The serum levels of triglycerides were not statistically 
different between the four genotypes (Table 5). 
Insulin, an anabolic pancreatic hormone, is secreted in response to increased blood 
glucose. This hormone signals the cells to increase glucose uptake, promotes 
glycogenesis in the liver and inhibits glucagon secretion from the pancreas, thus 
signaling the liver to stop producing glucose via glycogenolysis and gluconeogenesis 
(Aronoff et al., 2004). The serum levels of insulin were measured to determine if it could 
be a possible cause of the hypoglycemia observed in Nrf2/Hfe-/- mice, however there 
were no statistically significant differences between the four genotypes (Table 5). 
 
Table 5. Levels of glucose, triglycerides and insulin in the serum of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. 
 WT Nrf2-/- Hfe-/- Nrf2/Hfe-/- 
N 3 4 4 4 
Glucose (mg/dL) 64.3 ± 8.3 75.8 ± 9.2 77.8 ± 16.9 42.8 ± 11.4a,b 
Triglycerides (mg/dL) 67.3 ± 6.5 65.5 ± 21.3 66.0 ± 18.9 76.0 ± 11.8 
Insulin (μg/mL) 879.2 ± 633.8 560.6 ± 241.7 705.5 ± 217.7 539.3 ± 167.0 
Mean ± standard deviation. ap<0.05 vs. Nrf2-/-; bp<0.01 vs. Hfe-/-. 
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5. Expression of glucogenesis genes 
The key gluconeogenic enzymes are phosphoenolpyruvate carboxykinase (PEPCK-C) 
and glucose-6- phosphatase (G6Pc) (Samuel et al., 2009). The transcript levels of Pepck 
and G6pc were assessed in the liver and no significant differences were found (Figure 
11.A and 11.B). 
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Figure 11. Expression of gluconeogenesis genes in the liver of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. (A) Transcript levels 
of G6pc and (B) Pepck genes. 
 
6. Iron metabolism 
Hfe-/- mice provide an established model of systemic iron overload that mimics human 
HH (Bahram et al., 1999). Nrf2-/- mice are useful for studying oxidative stress responses, 
since the activation of ARE-containing genes by the transcription factor NRF2 is 
abrogated (Itoh et al., 1997). Hence, Nrf2/Hfe-/- mouse is a unique model for studying the 
effect of the oxidative stress generated by excessive iron. As expected, Hfe-/- mice 
presented significantly augmented serum iron compared to WT and Nrf2-/- mice 
(p<0.0001) (Figure 12.A). Transferrin saturation was also significantly elevated when 
compared to WT, Nrf2-/- (p<0.0001) and Nrf2/Hfe-/- mice (p<0.001) (Figure 12.B). It is 
worth noting that Nrf2/Hfe-/- mice did not present hyperferremia (augmented levels of 
serum iron), which would be expectable as the lack of the Hfe gene leads to systemic 
iron overload. 
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Figure 12. (A) Iron levels and (B) percentage of transferrin saturation in the serum of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- 
mice. 
A. B. 
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The transcript levels of hepcidin and the quantity of non-heme iron were assessed in 
the liver. Hamp mRNA levels in Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice were significantly 
decreased when compared to WT mice (p<0.05, p<0.05 and p<0.001, respectively) 
(Figure 13.D), what was expectable for Hfe-/- and Nrf2/Hfe-/- mice since HFE is necessary 
for hepcidin transcription (Ganz and Nemeth, 2012). The quantity of non-heme iron in 
the liver was significantly increased in Hfe-/- and in Nrf2/Hfe-/- mice when compared to 
WT and Nrf2-/- mice (p<0.001) (Figure 13.A). To evaluate whether the hepcidin 
expression was consistent with the hepatic iron stores, we divided the Hamp mRNA 
levels by the hepatic non-heme iron. This ratio was significantly decreased in Hfe-/- mice 
when compared to their WT counterparts (p<0.001) and in Nrf2/Hfe-/- mice when 
compared to WT (p<0.001) and Nrf2-/- (p<0.05) mice (Figure 13.E).  
The quantity of non-heme iron was also assessed in the spleen and kidneys. Spleen 
non-heme iron was not significantly different between the four genotypes (Figure 13.B). 
We noted a trend for increased iron content in the kidney of Nrf2 -/- and Nrf2/Hfe-/- mice, 
although this effect was not statistically significant (Figure 13.C). 
Perls’ Prussian Blue staining was used to determine the presence of iron in the 
spleen, kidney, heart and pancreas. As illustrated in Figure 14, the spleen of the four 
genotypes presented high amounts of iron, which is expectable since splenic 
macrophages are responsible for scavenging the senescent erythrocytes. However, iron 
appeared to be present in higher quantities in the kidney, heart and pancreas of Nrf2/Hfe-
/- mice when compared to WT, Nrf2-/- and Hfe-/- mice. It is worth noting that Nrf2/Hfe-/- 
pancreas accumulated iron in the exocrine pancreas (sparing the islets of Langherhans), 
siderophages and connective tissue. These data suggest that Nrf2/Hfe-/- mice 
accumulate more iron in the parenchyma of the different organs than the other 
genotypes. 
Perls’ Prussian Blue stained liver sections revealed the deposition of higher amounts 
of iron in Hfe-/- and Nrf2/Hfe-/- mice compared to WT and Nrf2-/- mice (Figure 15). These 
liver sections were graded according to the distribution of iron in hepatocytes, sinusoids 
and portal veins. As expected, Hfe-/- and Nrf2/Hfe-/- livers presented significantly 
increased amounts of iron in hepatocytes when compared to WT (p<0.0001 and p<0.05, 
respectively) and to Nrf2-/- (p<0.0001 and p<0.01, respectively) livers. It is worth noting 
that Hfe-/- hepatocytes presented significantly augmented iron levels than Nrf2/Hfe-/- 
hepatocytes (p<0.05) (Figure 16.A). Nrf2/Hfe-/- mice also presented significantly 
increased amounts of iron in the sinusoids when compared to WT (p<0.0001), Nrf2-/- 
(p<0.0001) and Hfe-/- (p<0.001) mice (Figure 16.B). Although portal iron was not 
statistically different between mice of the four genotypes, Hfe-/- and Nrf2/Hfe-/- livers 
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presented higher amounts of iron in macrophages, biliary cells and vascular walls in 
comparison with WT and Nrf2-/- livers (Figure 16.C). The total iron score, calculated as 
the sum of hepatic, sinusoidal and portal iron scores, was significantly augmented in Hfe-
/- and Nrf2/Hfe-/- livers when compared to WT (p<0.001 and p<0.0001, respectively) and 
Nrf2-/- (p<0.0001) livers (Figure 16.D). 
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Figure 13. (A) Tissue non-heme iron content in the liver (B) spleen and (C) kidney of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- 
mice. (D) Transcript levels of Hamp gene and (E) Hamp mRNA/Liver non-heme iron ratio of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-
/- livers.  
A. B. 
C. 
D. 
E. 
 Figure 14. Representative images of H&E and Perls’ Prussian Blue staining of spleen, kidney, heart and pancreas sections of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. Original magnification 100×. 
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Figure 15. H&E, Perls’ Prussian Blue and Sirius Red stained liver sections of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. Bar 
= 200 μm. 
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Figure 16. Histological grades of iron storage in WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- livers. (A) Hepatocytic iron score: 0-36. 
(B) Sinusoidal iron score: 0-12. (C) Portal iron score: 0-12. (D) Total iron score: 0-60.  
 
7. Oxidative stress 
Iron is a potential biohazard since, under aerobic conditions, it can readily catalyze the 
generation of ROS (Papanikolaou and Pantopoulos, 2005), which, in turn, can damage 
DNA, proteins and lipid membranes (Andrews, 1999). As the cellular antioxidant defense 
is essential to protect from oxidative damage, we decided to measure the quantity of total 
(GSX), reduced (GSH) and oxidized (GSSG) glutathione in the liver. Even though the 
quantity of GSX, GSH and GSSG was not statistically different between the four 
genotypes, the GSH/GSSG ratio was significantly decreased in Nrf2-/- mice when 
compared to Hfe-/- (p<0.05). A low GSH/GSSG ratio, even if not statistically significant, 
was also observed in Nrf2/Hfe-/- mice (Table 6). 
  
A. B. 
C. D. 
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Table 6. Levels of GSX, GSSG and GSH and GSH/GSSG ratio, in the serum of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. 
  WT Nrf2-/- Hfe-/- Nrf2/Hfe-/- 
N 6 8 5 7 
GSX (nmol/mg protein) 405.1 ± 84.9 263.8 ± 39.2 410.7 ± 104.5 268.9 ± 78.8 
GSSG (nmol/mg protein) 60.7 ± 2.6 52.7 ± 7.9 50.9 ± 7.2 50.6 ± 3.9 
GSH (nmol/mg protein) 283.6 ± 80.3 158.4 ± 33.0 308.9 ± 90.9 167.7 ± 85.3 
GSH/GSSG 4.6 ± 1.1 3.0 ± 0.7a 6.0 ± 1.0 3.4 ± 2.0 
Mean ± standard deviation. ap<0.05 vs Hfe-/-. 
 
Lipid peroxidation is one of the consequences of the oxidative stress caused by high 
amounts of iron. A Thiobarbituric Acid Reactive Substances (TBARS) assay was 
performed as an indirect measurement of malondialdehyde (MDA), a byproduct of lipid 
peroxidation. We found no significant differences in the MDA concentration across the 
four experimental groups (Figure 17.A). 
NRF2 is a key transcription factor involved in the antioxidant defense (Kensler et al., 
2007), so we decided to investigate the transcript levels of NAD(P)H:quinone 
oxireductase 1 (Nqo1), an antioxidant enzyme upregulated by NRF2 (Klaassen and 
Reisman, 2010), in the liver. As expected, Nrf2-/- and Nrf2/Hfe-/- livers showed 
significantly decreased levels of Nqo1 transcript when compared to WT and Hfe-/- livers 
(p<0.0001) (Figure 17.B). 
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Figure 17. (A) MDA concentration and (B) Nqo1 gene expression in the livers of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice.  
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8. Liver fibrosis 
Liver fibrosis is one of the major consequences of the excessive iron accumulation in HH 
patients and is characterized by excessive deposition of extracellular matrix (ECM) 
(Bataller and Brenner, 2005). Transforming growth factor (TGF)-β, the most prominent 
profibrotic cytokine that contributes to the development of hepatic fibrosis, signals the 
transcription of fibrogenic genes, such as collagen and fibronectin. In fibrotic liver, 
augmented (TGF)-β signaling stimulates transdifferentiation of hepatic stellate cells 
(HSCs) to α-smooth muscle actin (α-SMA)-positive myofibroblasts, the main producers 
of excessive ECM proteins. TGF-β is also capable of suppressing the activity of ECM 
degrading proteases, such as matrix metalloproteinases, via upregulation of their 
inhibitors, including tissue inhibitor of matrix metalloproteinase (TIMP)-1, leading to 
decreased ECM degradation (Oh et al., 2012). We evaluated the expression of genes 
involved in liver fibrosis, including alpha-smooth muscle actin (Acta2), type I collagen 
(Col1a1) and Timp1 genes. Levels of Acta2 and Timp1 genes were not statistically 
different in the livers of mice of the four genotypes (Figure 18.A and 18.C). However, 
the transcript levels of Col1a1 were significantly augmented in Nrf2/Hfe-/- mice when 
compared to Nrf2-/- mice (p<0.05) (Figure 18.B). 4-Hydroxyproline is a major component 
of collagen, comprising around 13.5% of its amino acid composition (Neuman and 
Logan, 1950), which is why we also determined the quantity of hydroxyproline in the liver. 
The quantity of hydroxyproline tended to augment in Nrf2/Hfe-/- mice in comparison to 
WT, Nrf2-/- and Hfe-/- mice (Figure 18.D). The hepatic fibrotic area was evaluated through 
a Sirius Red Staining. After analyzing three random microscope fields of the liver under 
polarized light, obtained at 100× magnification, we observed that the percentage of 
fibrotic area was significantly increased in Nrf2/Hfe-/- mice compared to WT (p<0.05), 
Nrf2-/- and Hfe-/- mice (p<0.01) (Figure 18.E). 
Sirius Red stained liver sections were also graded according to the level of fibrosis. 
As illustrated in Figure 15, Nrf2/Hfe-/- mice presented a more exuberant phenotype of 
fibrosis (bridging fibrosis) than WT, Nrf2-/- and Hfe-/- mice. Fibrosis degree was 
significantly augmented in Nrf2/Hfe-/- livers in comparison to WT (p<0.01), Nrf2-/- (p<0.05) 
and Hfe-/- (p<0.001) livers (Figure 19). 
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Figure 18. Hepatic fibrosis and expression of fibrogenic genes in the livers of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. (A) 
Transcript levels of Acta2 (B) Col1a1 and (C) Timp1 genes in the liver. (D) Hepatic quantity of hydroxyproline and (E) 
percentage of hepatic fibrotic area. 
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Figure 19. Fibrosis degree of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- livers. Fibrosis degree: 0. none. 1. mild/moderate in zone 
3, portal/periportal only. 2. portal/periportal and perisinusoidal 3. bridging fibrosis. 4. cirrhosis. 
A. B. 
C. D. 
E. 
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9. Hepatic inflammation and steatosis 
During local liver injury, resident Kupffer cells initiate an immune response, releasing a 
variety of chemical messengers such as cytokines, like tumour necrosis factor alpha 
(TNFα) and interleukin (IL)-6, and chemokines, such as CCL-2, that initiate the acute-
phase response and inflammation (Liaskou et al., 2012). Besides, it is known that NRF2 
is involved in the inhibition of inflammation (Kensler et al., 2007). To evaluate liver 
inflammation, the transcript levels of Tnf-α, Il-6 and Ccl-2 genes were assessed in the 
liver. No significant differences in the transcript levels of Tnf-α and Ccl2 genes were 
found and (Figure 20.A and 20.B), contrary to expected, Nrf2-/- and Nrf2/Hfe-/- livers 
showed decreased levels of Il-6 in comparison to WT livers (p<0.05) (Figure 20.C). 
H&E staining was applied to assess hepatic inflammation and steatosis. H&E stained 
liver sections are presented in Figure 15. No significant differences were found in the 
lobular inflammation degree of the four genotypes (Figure 21.A). These data suggest 
that the low levels of inflammation found in the liver may be due to the advanced age of 
the model. Steatosis degree was significantly augmented in Hfe-/- livers compared to WT, 
Nrf2-/- and Hfe/Nrf2-/- livers (p<0.0001) (Figure 21.B), fact that was previously reported 
by other authors (Tan et al., 2011). Steatosis was localized in the liver Rappaport zone 
one (periportal). 
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Figure 20. Expression of proinflammatory genes in the liver of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. (A) Transcript levels 
of Tnf-α (B) Ccl2 and (C) Il-6 genes. 
A. B. 
C. 
46 
 
FCUP 
NRF2 protection against liver injury in human and mouse models of HH 
 
 
L
o
b
u
la
r
 i
n
fl
a
m
m
a
t
io
n
 d
e
g
r
e
e
W
T
N
rf
2
- /
-
H
fe
- /
-
N
rf
2
/H
fe
- /
-
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
S
t
e
a
t
o
s
is
 d
e
g
r
e
e
W
T
N
rf
2
- /
-
H
fe
- /
-
N
rf
2
/H
fe
- /
-
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
p < 0 .0 0 0 1
p < 0 .0 0 0 1
p < 0 .0 0 0 1
 
Figure 21. H&E grading of lobular inflammation and steatosis in WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- liver sections. (A) Lobular 
inflammation degree: 0. no foci; 1. <4 foci per 100× field; 2. 4-8 foci per 100× field; 3. >8 per 100× field. (B) Steatosis 
degree: 0. absent (<5% of parenchyma); 1. light (5-33% of parenchyma); 2. moderate (33-66% of parenchyma); 3. severe 
(>66% of parenchyma). 
 
10. Liver damage 
Alanine aminotransferase (ALT) activity, a serum marker for liver damage, was 
assessed. We found no statistical differences between the four genotypes (Figure 22.A). 
Hepatic cell death was assessed through a Terminal deoxynucleotidyl transferase (TdT) 
dUTP Nick-End Labeling (TUNEL) assay, which detects DNA fragmentation. The 
number of TUNEL-positive cells was significantly increased in Nrf2/Hfe-/- mice when 
compared to WT mice (p<0.05) (Figure 22.B). Representative images of each group and 
positive and negative controls for the TUNEL assay are presented in Figure 23. 
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Figure 22. Levels of (A) serum ALT and (B) TUNEL-positive cells in the liver of WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- mice. 
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Figure 23. TUNEL assay. Positive and negative controls and representative liver sections of WT, Nrf2-/-, Hfe-/- and 
Nrf2/Hfe-/- mice. Original magnification: 400×. 
 
The degree of liver necrosis was assessed in the H&E stained liver sections. Of note, 
confluent necrosis was observed in 6 out of the 7 Nrf2/Hfe-/- individuals, which thus 
exhibited significantly more hepatocellular necrosis than WT, Nrf2-/- and Hfe-/- mice 
(p<0.0001) (Figure 24.C). 
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Figure 24. Representative H&E stained liver sections of Nrf2/Hfe-/- mice showing (A) spotty necrosis and (B) confluent 
necrosis. (C) H&E grading of necrosis in WT, Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- liver sections. 0. absent. 1. spotty necrosis (one 
or a few necrotic hepatocytes). 2. confluent necrosis. 3. bridging necrosis. 
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Human study 
In order to properly perform the SNP genotyping of Rs35652124, Rs670664, 
Rs150648896 and Rs6721961 of the NRF2 promoter region, the first approach was to 
optimize the PCR protocol to avoid the appearance of non-specific bands in the 
electrophoresis gel. Different enzymes (Taq DNA Polimerase from ThermoFisher 
Scientific, Lithuania; Type-it® Microsatellite PCR Kit from Qiagen, Germany), annealing 
temperatures (61-63 ºC), annealing and extension time (1 min and 30 s) and 
concentrations of MgCl2 (1.5 and 2mM) and template DNA (10, 50 and 100 ng/μL) were 
tested. A single PCR product was consistently obtained when using the Type-it® 
Microsatellite PCR Kit, increasing the annealing temperature to 63ºC, decreasing the 
annealing and extension time for 30 s and setting the template DNA at 50 ng/μL. 
Representative agarose gel from the original protocol and from the optimized one are 
presented in Figure 25. 
 
 
Figure 25. PCR amplification of a 284 bp fragment of the NRF2 promoter region. PCR products were separated by gel 
electrophoresis and visualized under UV after ethidium bromide staining. Representative images of the PCR products 
obtained (A) prior to and (B) after optimization are depicted. 
 
The PCR fragment was genotyped and the SNPs were determined with ProSeq3 
software. An example of an electropherogram is presented in Figure 26. Allele 
frequencies of Rs35652124 (T > C), Rs670664 (C > T), Rs150648896 (C > T) and 
Rs6721961 (G > T) SNPs were calculated in unrelated patients, as described in Materials 
and Methods (M&M). Frequencies of the actual sample and reference frequencies from 
Ensembl are presented in Table 7. We concluded that there were no significant 
differences between the frequencies of the actual sample and the frequencies reported 
in Ensembl for the European population. 
As a first approach to address the genotype/phenotype correlations, we estimated the 
allele frequencies of the different SNPs in groups of patients divided according to the 
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expression of specific clinical manifestations of disease, as described in M&M. The 
respective allele frequencies are presented in Table 8.  
 
 
Figure 26. Representative elecropherogram. The R inside a square represents a heterozygote individual for Rs35652124 
SNP. 
 
Table 7. Actual sample and reference allele frequencies. 
 
Table 8. Allele frequencies in patients stratified according to the clinical manifestations of disease. 
 
Although, in general, no statistically significant differences were found among groups, 
it is worth noting that the frequency of the allele T in Rs35652124 SNP was higher in 
patients with cirrhosis (presence of cirrhosis +) and in symptomatic patients than in 
patients without cirrhosis (presence of cirrhosis −) or asymptomatic patients (Table 8).  
 
Actual sample Reference 
Rs35652124 Rs6706649 Rs150648896 Rs6721961 Rs35652124 Rs6706649 Rs150648896 Rs6721961 
freq (T) 0.680 (132) 0.103 (20) 0.000 (0) 0.098 (19) 0.694 (698) 0.111 (112) 0.000 (0) 0.125 (126) 
freq (C) 0.320 (62) 0.897 (174) 1.000 (194)  0.306 (308) 0.889 (894) 1.000 (1006)  
freq (G)    0.902 (175)    0.875 (880) 
Frequency (number of alleles). The reference frequencies were obtained in Ensembl for the European population. 
 
Presence of Cirrhosis Presence of Arthropathy Clinical Presentation 
+ − + − Symptomatic Assymptomatic 
n 11 46 11 46 24 33 
Rs35652124 
freq (T) 0.818 (18) 0.641 (59) 0.682 (15) 0.674 (62) 0.750 (36) 0.621 (41) 
freq (C) 0.182 (4) 0.359 (33) 0.318 (7) 0.326 (30) 0.250 (12) 0.379 (25) 
Rs6706649 
freq (T) 0.182 (4) 0.141 (13) 0.091 (2) 0.163 (15) 0.146 (7) 0.152 (10) 
freq (C) 0.818 (18) 0.859 (79) 0.909 (20) 0.837 (77) 0.854 (41) 0.848 (56) 
Rs150648896 
freq (T) 0.000 (0) 0.000 (0) 0.000 (0) 0.000 (0) 0.000 (0) 0.000 (0) 
freq (C) 1.000 (22) 1.000 (92) 1.000 (22) 1.000 (92) 1.000 (48) 1.000 (66) 
Rs6721961 
freq (T) 0.045 (1) 0.065 (6) 0.136 (3) 0.043 (4) 0.104 (5) 0.030 (2) 
freq (G) 0.955 (21) 0.935 (86) 0.864 (19) 0.957 (88) 0.896 (43) 0.907 (64) 
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The frequency of each genotype was next calculated in all unrelated patients (Table 
9). The T/C-C-C-G genotype was the most frequent, while the T-T/C-C-T/G was the 
rarest one. 
 
Table 9. Frequencies of the several genotypes in 97 patients. 
Genotype n freq 
T/C-C-C-G 28 0,289 
T-C-C-G 22 0,227 
T-C-C-T/G 13 0,134 
C-C-C-G 12 0,124 
T-T/C-C-G 8 0,082 
T/C-C-C-T/G 5 0,052 
T/C-T/C-C-G 5 0,052 
T-T-C-G 3 0,031 
T-T/C-C-T/G 1 0,010 
Genotype: Rs35652124-Rs670664-Rs150648896-Rs6721961. 
 
As for allele frequencies, genotype frequencies were also calculated in relation to the 
clinical phenotype, i.e., for groups of patients with cirrhosis, arthropathy or any 
manifestations (Table 10). Although not statistically significant, the total number 
genotypes homozygous for allele T in Rs35652124 SNP (Total TT) was higher in patients 
with cirrhosis, arthropathy and symptomatic patients than in patients without these 
features. Accordingly, the total number of genotypes with allele C in homozygosity or 
heterozygosity in Rs35652124 SNP (Total with C) was increased in patients without 
cirrhosis, arthropathy or asymptomatic. 
Since the previous results suggested that the allele C in Rs35652124 SNP may have 
a protective effect in HH patients, we further analyzed data comparing genotypes 
homozygous for allele T (Total TT) and genotypes homozygous/heterozygous for allele 
C (Total with C) in Rs35652124 SNP. For that purpose, we compared the two genotype 
groups (Total TT and Total with C) for the following variables: age, iron parameters, total 
lymphocytes and lymphocyte subsets (CD4+ and CD8+) and the clinical manifestations 
of the disease. As described in M&M, for all the clinical variables analyzed, 
asymptomatic, early diagnosed females and young males (<30 years of age) were 
excluded. For the specific purpose of estimating the frequency of cirrhosis, the cases 
where we had no confirmatory liver biopsy available were also excluded. The results are 
summarized in Table 11. 
52 
 
FCUP 
NRF2 protection against liver injury in human and mouse models of HH 
 
Table 10. Genotype frequencies in patients with or without cirrhosis, arthropathy and symptoms. 
 
Presence of Cirrhosis Presence of Arthropathy Clinical Presentation 
+ - + - Symptomatic Assymptomatic 
n freq n freq n freq n freq n freq n freq 
T-C-C-G 3 0,273 8 0,174 3 0,273 8 0,174 5 0,208 6 0,182 
T-C-C-T/G 1 0,091 4 0,087 2 0,182 3 0,065 4 0,167 1 0,030 
T-T/C-C-G 3 0,273 5 0,109 0 0,000 8 0,174 4 0,167 4 0,121 
T-T-C-G 0 0,000 3 0,065 1 0,091 2 0,043 1 0,042 2 0,061 
T-T/C-C-T/G 0 0,000 1 0,022 0 0,000 1 0,022 0 0,000 1 0,030 
Total TT 7 0,636 21 0,457 6 0,545 22 0,478 14 0,583 14 0,424 
T/C-C-C-G 3 0,273 15 0,326 2 0,182 16 0,348 6 0,250 12 0,364 
T/C-C-C-T/G 0 0,000 1 0,022 1 0,091 0 0,000 1 0,042 0 0,000 
T/C-T/C-C-G 1 0,091 1 0,022 0 0,000 2 0,043 1 0,042 1 0,030 
C-C-C-G 0 0,000 8 0,174 2 0,182 6 0,130 2 0,083 6 0,182 
Total with C 4 0,364 25 0,543 5 0,455 24 0,522 10 0,417 19 0,576 
Genotype: Rs35652124-Rs670664-Rs150648896-Rs6721961. Total TT: genotypes homozygous for allele T in 
rs35652124. Total with C: genotypes with allele C in homozygosity or heterozygosity in Rs35652124 SNP. 
 
Table 11. Clinical characterization of the genotypes groups. 
 
Total TT Total with C Significant level 
n 20 16  
Age 48 ± 12 46 ± 8  
Ferritin (ng/mL) 2378 ± 1928 1550 ± 976  
TfSat (%) 80 ± 20 86 ± 19  
TBIS (g) 9.6 ± 5.2 4.8 ± 2.6 p=0,01 
Lymphocytes 1.70 ± 0.68 2.18 ± 0.66  
CD4+ 0.76 ± 0.33 0.97 ± 0.29  
CD8+ 0.40 ± 0.28 0.47 ± 0.19  
Frequency of the clinical manifestations   
Skin pigmentation 5/16 (31.3%) 2/13 (15.4%)   
Diabetes 2/16 (12.5%) 1/13 (7.7%)   
Hypogonadysm 1/16 (6.3%) 0/13 (0%)   
Arthropathy 3/16 (18.8%) 1/16 (6.3%)   
Cirrhosis 7/16 (43.8%) 0/13 (0%) p = 0.05 
Any clinical manifestations 8/16 (50.0%) 2/13 (15.4%)  
Mean ± standard deviation. Total TT: genotypes homozygous for allele T in rs35652124. Total with C: genotypes with 
allele C in homozygosity or heterozygosity in Rs35652124 SNP. TfSat (%): transferrin saturation. TBIS: total body iron 
stores. ap = 0.01 vs genotypes with allele C in homozygosity or heterozygosity in Rs35652124 SNP. 
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No significant differences were found between the two groups in terms of age, 
biochemical and hematological parameters. However, TBIS was significantly increased 
in genotypes homozygous for allele T in Rs35652124 SNP (Total TT) when compared 
to genotypes homozygous/heterozygous for allele C in Rs35652124 SNP (Total with C) 
(p = 0.01) (Table 11). Cirrhosis was significantly increased in genotypes homozygous 
for allele T in Rs35652124 SNP (Total TT) when compared to genotypes 
homozygous/heterozygous for allele C in Rs35652124 SNP (Total with C) (p = 0.5). 
Although not statistically significant, symptomatic patients had more commonly 
genotypes homozygous for allele T in Rs35652124 SNP (Total TT) (p = 0.10).
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Discussion 
 
Animal study 
1. Hfe and Nrf2 genes in erythropoiesis 
Hfe-/- mice exhibited significantly higher levels of Hb and HCT when compared to WT 
mice. These data are in agreement with several reports that showed erythropoietic 
alterations in HH patients, including increased Hb levels, reticulocyte counts, HCT, MCV, 
MCH, and MCH concentration (Barton et al., 2000; Feeney et al., 2005; McLaren et al., 
2007). A study by Ramos et al., 2011 demonstrated that the Hfe gene influences 
erythropoiesis by limiting hepcidin expression under conditions of simultaneous iron 
overload and stress erythropoiesis, and by impairing transferrin-bound iron uptake by 
erythroid cells. This dual role for Hfe avoids the toxicity associated with iron overload 
under conditions of high iron availability and limits erythroid iron intake under conditions 
of iron deficiency (Ramos et al., 2011). 
In contrast with Hfe-/- mice, Nrf2/Hfe-/- mice presented low values of RBC, Hb and 
HCT, which indicates that they were mildly anemic. Their MCV and MCH values were 
increased, indicating that the anemia was macrocytic and normochromic. Macrocytic 
anemia is characterized by the presence of abnormally large RBCs in the peripheral 
blood and can be divided into two categories, megaloblastic and nonmegaloblastic, 
based on the examination of the bone marrow. The etiologies associated with macrocytic 
anemia include nutritional deficiencies (e.g., vitamin B12 and folate), drugs, primary bone 
marrow disorders (e.g., myelodysplasia and leukemia) and other chronic illnesses (e.g. 
alcoholism and hypothyroidism). Megaloblastic anemia is highly suspicious of a vitamin 
B12 or folate deficiency and is characterized by large and oval shaped erythroblasts that 
contain a characteristic immature, lacy nucleus (Aslinia et al., 2006). Nrf2/Hfe-/- mice had 
the lowest body weight, so we suspected that the anemia could be due to low intestinal 
absorption of nutrients, namely vitamin B12 and folate. This hypothesis was excluded 
since megaloblasts were not observed in bone marrow smears (Tiago Duarte, personal 
communication). The percentage of reticulocytes was increased in Nrf2/Hfe-/- mice, 
indicative of a regenerative anemia. With regenerative anemia, the bone marrow 
responds appropriately to the decreased red cell mass by increasing RBC production 
and releasing reticulocytes. Typically, regenerative anemia is caused by hemorrhage or 
hemolysis (Kahn, 2010). Serum LDH activity was not altered in Nrf2/Hfe-/- mice, which 
indicates that the anemia did not result from RBC hemolysis. 
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Erythroid colony-forming units adhere to a resident macrophage and differentiate to 
erythroblasts in the presence of EPO, resulting in the formation of an erythroblastic 
island. So, resident macrophages play a supportive role in erythropoiesis, probably by 
preventing apoptosis of the erythroid precursors (Sadahira and Mori, 1999), and EPO 
stimulates the erythroid progenitors in the bone marrow to proliferate (Beguin et al., 
1993). Transcript levels of Epo gene in the kidney and EPO levels in the serum were 
slightly augmented, even if not statistically significant, in Nrf2/Hfe-/- mice. This indicates 
that the kidney was responding to the low levels of RBC and that erythropoiesis was not 
compromised due to lack of EPO. Spic transcript levels were not altered in the liver and 
spleen of Nrf2/Hfe-/- mice and F4/80 transcript levels were also not altered in the spleen 
of Nrf2/Hfe-/- mice. These data indicate that the anemia was not caused by lack of 
macrophages to nurse the development and differentiation of erythroid cells. HO-1 is 
responsible for the disposal of the potentially toxic heme (Fraser et al., 2011). HO-1 
deficiency in humans appears to be an extremely rare condition with only two live births 
reported. Both patients presented severe anemia (Kartikasari et al., 2009; Yachie et al., 
1999). Nrf2/Hfe-/- mice did not present significant alterations in the levels of Hmox1 in the 
liver and spleen, which indicates that the anemia did not result from lack of HO-1. 
The pro-inflammatory state of aging may result in anemia (Roy, 2010). Since mice 
employed in the study were 24 months of age, anemia of inflammation (AI) could be a 
possible cause of the low RBC count in Nrf2/Hfe-/- mice. AI is typically normochromic and 
normocytic and is characterized by low serum iron and reticulocyte count, decreased 
transferrin saturation and bone marrow sideroblasts and increased reticuloendothelial 
iron and hepcidin levels (Cartwright, 1966). In certain cases, EPO production is not 
sufficiently increased relative to the severity of the anemia and erythrocyte life span is 
decreased (Roy, 2010). These features of AI suggest that the immune response 
promotes iron sequestration, but also inhibits the production and survival of erythrocytes 
(Weiss and Goodnough, 2005). Cytokines, such as IL-6, TNFα and IL-1, are linked to AI. 
IL-6 correlates with hemoglobin concentration and TNFα and IL-1 have been implicated 
in the inhibition of multiple stages of erythroid development (Weiss and Goodnough, 
2005). The hypothesis that Nrf2/Hfe-/- mice could have AI was excluded. Even though 
they presented low levels of serum iron and decreased transferrin saturation when 
compared to Hfe-/- mice (they should have presented higher values due to the lack of 
HFE), reticulocyte count was not decreased, Hamp transcript levels in the liver were not 
increased and the levels of GM-CSF, IFN-γ, IL-1b, IL-6, IL-10, MCP-1 and TNFα were 
not significantly increased. These data lead us to discard the AI. 
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Iron deficiency anemia (IDA) is characterized by microcytosis and hypochromasia 
with inadequate regeneration, and low serum iron, iron saturation and ferritin 
(Naigamwalla et al., 2012). As Nrf2/Hfe-/- mice had low body weight and low serum iron 
levels, the decreased iron intestinal absorption could be the source of the anemia. 
However IDA was also excluded since the anemia was macrocytic, normochromic and 
regenerative. The fact that the Nrf2/Hfe-/- mice anemia is regenerative is by itself an 
exclusion factor for IDA, since there must exist available iron for the development of 
reticulocytes. 
Further investigation needs to be done to determine the origin of the anemia of 
Nrf2/Hfe-/- mice. NRF2 has been proven to play a critical role in the survival of RBCs, by 
regulating intracellular ROS levels when selenoproteins, enzymes with antioxidant 
properties, are depleted (Kawatani et al., 2011). So, we can only speculate that the lack 
of both Nrf2 and Hfe genes prompt the mice to the development of anemia, since Hfe is 
essential to balance the iron uptake by RBC and Nrf2 is needed to increase RBC survival 
in the presence of ROS. 
 
2. Hfe and Nrf2 genes in gluconeogenesis 
It has been demonstrated that the targeted inactivation of the Hfe gene in mice results 
in decreased insulin secretory capacity (Cooksey et al., 2004). Iron overload is common 
in type 2 diabetes (Fernandez-Real et al., 2002; Ford and Cogswell, 1999; Forouhi et al., 
2007) and the most commonly studied model for iron associated diabetes is HH (Huang 
et al., 2011). Conversely, iron depletion seems to be protective against the development 
of diabetes (Huang et al., 2011). In contrast to previous descriptions of diabetes in Hfe-/- 
mice in the literature, in our study Hfe-/- mice were not diabetic and Nrf2/Hfe-/- mice were 
hypoglycemic, as they presented significantly decreased serum glucose at starvation. 
Moreover, Hfe-/- and Nrf2/Hfe-/- mice presented normal values of insulin when compared 
to WT mice. As insulin is responsible for the reduction of plasma glucose levels, and no 
significant differences were found in mice of the four genotypes, we can conclude that 
insulin levels were not the cause of the hypoglycemia of Nrf2/Hfe-/- mice. To further 
investigate the hypoglycemia in Nrf2/Hfe-/- mice, we aimed to determine if a defect in 
gluconeogenesis was the origin of the low levels of glucose. Gluconeogenesis is de novo 
synthesis of glucose from noncarbohydrate precursors, such as lactate, pyruvate, 
glycerol and alanine. The rate of gluconeogenesis is controlled principally by the 
activities of PEPCK, fructose-1,6-bisphosphatase and glucose-6-phosphatase (Yoon et 
al., 2001). No significant differences were detected in G6pc and Pepck transcript levels 
in Nrf2/Hfe-/- liver. Hence, we have no evidence that the hypoglycemia of Nrf2/Hfe-/- mice 
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was due to compromised gluconeogenesis. It is thus possible that the hypoglycemia at 
starvation is simply the result of the worse body condition of Nrf2/Hfe-/- mice, which is 
illustrated by the decreased body weight when compared to all the other genotypes. 
Further investigation should be done to clarify the origin of the low levels of glucose in 
Nrf2/Hfe-/- mice.  
 
3. Hfe and Nrf2 genes in iron metabolism 
The Hfe-/- mouse is a model of systemic iron overload and mimics human HH (Bahram 
et al., 1999). As expected, Hfe-/- mice presented significantly augmented serum iron and 
transferrin saturation when compared to other genotypes. However, Nrf2/Hfe-/- mice did 
not present augmented levels of these parameters as would be expectable since the lack 
of Hfe gene deregulates hepcidin expression and leads to systemic iron overload. The 
surprisingly low levels of serum iron in Nrf2/Hfe-/- mice were not observed in younger 
animals (Tiago Duarte, personal communication) and may be a consequence of the 
anemia. The increased bone marrow iron demand (for erythrocyte production) may have 
contributed to these low levels. Likewise, since there are less erythrocytes being recycled 
by macrophages, consequently, less iron is expected to be released into the 
bloodstream. The lack of Nrf2 gene seems to have no influence on serum iron and 
transferrin saturation, as the values of Nrf2-/- mice were identical to the ones of WT mice. 
Nrf2-/-, Hfe-/- and Nrf2/Hfe-/- livers presented significantly decreased Hamp mRNA 
levels in comparison with WT livers. Low levels of Hamp transcript in Hfe-/- and Nrf2/Hfe-
/- livers were expected, since it was previously reported that the hepatic expression of 
hepcidin is inappropriately low in the Hfe-/- mouse (Ahmad et al., 2002). However, lower 
levels were not expected for Nrf2-/- mice. Further investigation needs to be done to 
determine if the Nrf2 gene is involved in the regulation of Hamp transcription. The amount 
of non-heme iron in the liver was significantly augmented in Hfe-/- and Nrf2/Hfe-/- mice 
when compared to Nrf2-/- and WT mice. The increased hepatic non-heme iron, a feature 
of Hfe-/- model (Bahram et al., 1999), was likely due to the decreased hepcidin 
expression, which allows increased intestinal iron uptake and its delivery to plasma, 
resulting in increased Tf saturation and tissue iron accumulation. The Hamp mRNA/Liver 
non-heme Fe ratio is a measure of whether the hepcidin expression is adequate to the 
hepatic iron stores. The ratio was significantly decreased in Hfe-/- and Nrf2/Hfe-/- mice 
when compared to WT mice. These data indicate that the hepcidin expression is 
insufficient to face the hepatic iron content of Hfe-/- and Nrf2/Hfe-/- mice, which is in 
agreement with the lack of Hfe gene. It also indicates that, despite Nrf2-/- mice presenting 
low levels of Hamp mRNA, the hepcidin expression is in agreement with the hepatic iron 
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content. A previous study by Ahmad et al., 2002 have already reported that the normal 
relationship between iron stores and liver hepcidin expression is altered with the loss of 
Hfe gene (Ahmad et al., 2002). The spleen and kidney non-heme iron contents were not 
significantly different between the mice of the four genotypes, indicating that the non-
heme iron content of these organs is not influenced by the genotype. 
Perls’ Prussian Blue staining revealed that the spleen of the mice of the four 
genotypes accumulated high amounts of iron, whereas iron deposition was only detected 
in the kidney, heart and pancreas of Nrf2/Hfe-/- mice. The spleen is an organ known to 
accumulate large amounts of iron, as spleen macrophages are the main responsible for 
erythrophagocitosis (Knutson and Wessling-Resnick, 2003). Our findings are surprising, 
since Nrf2/Hfe-/- mice are mildly anemic, but also presented large amounts of iron in 
Perls’ Prussian Blue staining. Nrf2/Hfe-/- mice seem to accumulate higher amounts of 
iron in the parenchyma of the several organs than the other genotypes, in spite of the 
anemia. 
Liver sections stained with Perls’ Prussian Blue revealed higher amounts of iron 
deposits (hemosiderin) in Hfe-/- and Nrf2/Hfe-/- mice than in Nrf2-/- and WT mice. 
Hepatocytic iron was significantly increased in Hfe-/- and Nrf2/Hfe-/- mice when compared 
to WT and Nrf2-/-, but the amount of iron in the hepatocytes of Hfe-/- mice was significantly 
higher than the one in Nrf2/Hfe-/-. Hepatocytes are an important site of iron storage in the 
form of ferritin, so it was already expected that Hfe-/- and Nrf2/Hfe-/- hepatocytes 
presented high amounts of iron, since the lack of HFE leads to increased iron uptake. 
What was an interesting finding was the fact that the Hfe-/- hepatocytes presented higher 
levels of iron than Nrf2/Hfe-/- hepatocytes. These finding can be related to the anemia of 
the Nrf2/Hfe-/- mice, since there was less iron in circulation and, consequently, less iron 
to be stored in ferritin. On the other hand, sinusoidal iron was only augmented in Nrf2/Hfe-
/- mice. Sinusoidal iron corresponds to deposits of iron in Kupffer cells and endothelial 
cells inside the liver sinusoids. A characteristic feature of mouse models of HH is the 
iron-deficient phenotype of their macrophages, enterocytes and adipocytes in spite of 
systemic iron overload (Fleming and Ponka, 2012). The presence of iron in Nrf2/Hfe-/- 
sinusoids was unexpected, not only because of the iron-depletion phenotype expected, 
but also because of the anemia. We can hypothesize that the lack of Nrf2 somehow 
modulates iron metabolism in Hfe-/- mice, by shifting iron deposition from the liver 
parenchyma to the sinusoidal cells. Possible explanations for this shift are the 
phagocytosis of dead hepatocytes or increased erythrophagocytosis by sinusoidal cells. 
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4. Hfe and Nrf2 genes and oxidative stress 
The liver is capable of accumulating high amounts of iron. The excess free iron leads to 
liver damage due to ROS formation. NRF2 upregulates many cytoprotective enzymes 
that take part in the antioxidant response and plays an important role in the hepatic aging 
process. It has been demonstrated that age-related decrease in resistance to oxidative 
stress results from the lower expression of antioxidant enzymes, including GPx, GR, 
CAT, and NQO1 (Shih and Yen, 2007). Furthermore, with age, there is a substantial 
reduction in glutathione (GSH) levels and in the expression and activity of glutamate 
cysteine ligase, the rate controlling enzyme in GSH synthesis (Suh et al., 2004). These 
events are accompanied by lower levels of NRF2 protein and a reduction in NRF2/ARE 
binding, as well as increased markers of protein and lipid oxidation (Shih and Yen, 2007; 
Suh et al., 2004). The reason why aging organisms gradually lose the ability to activate 
NRF2 is currently not understood (Hayes and Dinkova-Kostova, 2014), but a decline in 
NRF2 signaling is presumed to contribute to the age-related hepatic oxidative stress. 
Transcript levels of Nqo1 showed a significant decrease in Nrf2 -/- and Nrf2/Hfe-/- livers 
when compared to WT and Hfe-/- livers. This result was expected since the antioxidant 
enzyme NQO1 is upregulated by NRF2. GSX, GSH and GSSG did not show significant 
differences between the livers of the four genotypes. However, the GSH/GSSG ratio was 
significantly decreased in Nrf2-/- livers when compared to Hfe-/- livers. This ratio 
represents the balance between the reduced form of glutathione (GSH) and the oxidized 
one (GSSG). A predominance of the oxidized form is suggestive of oxidative stress. 
GSH/GSSG ratio was expected to be low in the absence of Nrf2 gene, so it is surprising 
that Nrf2/Hfe-/- livers did not present an even lower ratio. MDA concentration, a marker 
of lipid peroxidation, did not show significant differences between the livers of the four 
genotypes. The lack of differences in MDA concentration may be possibly due to the late 
age of the model, since, as mentioned before, the markers of lipid peroxidation tend to 
augment with age.  
 
5. Hfe and Nrf2 genes in liver fibrosis 
One of the main consequences of HH is liver fibrosis, the accumulation of extracellular 
matrix or scar tissue in the liver. Even if not statistically significant, the levels of Acta2 
transcript were slightly augmented in Nrf2/Hfe-/- mice. This indicates that HSCs are being 
transdifferentiated to α-SMA-positive myofibroblasts, the main producers of ECM. 
Col1a1 gene, one of the genes involved in liver fibrosis, and the percentage of liver 
fibrotic area were significantly augmented in Nrf2/Hfe-/- mice compared to Nrf2-/- mice 
and to WT, Nrf2 -/- and Hfe-/- mice, respectively. Hydroxiproline, the major component of 
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collagen, and TIMP-1, an inhibitor of matrix metalloproteinases (responsible for ECM 
degradation), were also slightly augmented in Nrf2/Hfe-/- mice. The degree of fibrosis 
was further assessed in liver sections stained with Sirius Red. Fibrosis was more 
exuberant in Nrf2/Hfe-/- mice. While in WT, Nrf2 -/- and Hfe-/- livers fibrosis was 
mild/moderate and localized in zone 3 or in portal/periportal areas, Nrf2/Hfe-/- livers 
presented bridging fibrosis, with collagen fibers linking portal and central veins. These 
data are compatible with augmented production of ECM and decreased ECM 
degradation in Nrf2/Hfe-/- mice. It is worth noting that the amount of non-heme Fe present 
in the liver of Hfe-/- and Nrf2/Hfe-/- mice was very similar, but the former are protected 
from fibrosis. Our findings thus indicate that Nrf2 gene is important in the progression of 
HH. 
 
6. Hfe and Nrf2 genes in liver inflammation and steatosis 
Increased iron stores are correlated with markers of chronic inflammation and the 
adaptation to iron deficiency confers resistance to infection and improves the 
inflammatory condition. Hepcidin is upregulated by inflammatory stress response 
pathways and triggers systemic iron withdrawal and sequestration due to ferroportin 
down-regulation (Wessling-Resnick, 2010). Despite the large contribution of hepcidin, 
other stress response pathways also participate in the inflammatory response, including 
cytokine-mediated effects elicited by tumor necrosis factor-α (TNF-α) and interferon-γ 
(IFN-γ) (Weiss, 2009). During inflammation, several cytokines, like IL-6, and 
chemokines, such as CCL-2, are released (Liaskou et al., 2012). Although no significant 
differences were detected in the levels of Tnf-α and Ccl2 genes in the livers of the mice 
of the four genotypes, significantly decreased levels of Il-6 transcript were detected in 
Nrf2-/- and Nrf2/Hfe-/- livers when compared to WT and Hfe-/- livers. These results were 
not expected, since NRF2 is reported to have an anti-inflammatory role (Kensler et al., 
2007). We expected to see higher levels of markers of inflammation in Nrf2-/- and 
Nrf2/Hfe-/- livers, since the antioxidant defense is compromised due to the lack of NRF2. 
Nevertheless, despite of the low transcript levels of cytokines and chemokines in the liver 
of Nrf2-/- and Nrf2/Hfe-/- mice, the levels of GM-CSF, IFN-γ, IL-1b, IL-6, IL-10, MCP-1 and 
TNF-α were, although not significantly, augmented in Nrf2-/- serum. These data show us 
that Nrf2-/- mice present slightly higher levels of pro-inflammatory cytokines and 
chemokines than the mice of the other genotypes. Lobular inflammation was assessed 
in H&E stained liver sections and no significant differences were found, which indicates 
that the low levels of inflammation seen in the livers of the four genotypes must be a 
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consequence of the advanced age of the model rather than a consequence of the 
genotype. 
Steatosis is commonly observed in HFE-related iron-overload disorders, like HH, and 
current evidence suggests a causal link between iron and steatosis (Tan et al., 2011). 
Excessive iron causes oxidative stress that leads to mitochondrial dysfunction, impaired 
fatty acid (FA) oxidation and subsequent development of steatosis (Rector et al., 2010). 
In this study, steatosis was significantly augmented in Hfe-/- livers when compared to WT 
and Nrf2-/- livers. Tan et al., 2011 have already reported an augment of steatosis degree 
in Hfe-/- mice when compared to WT mice (Tan et al., 2011). Steatosis was not observed, 
however, in Nrf2/Hfe-/- mice, possibly as a consequence of their low body 
weight/condition. 
 
7. Hfe and Nrf2 genes and liver damage 
Oxidative stress affects liver function, induces hepatocyte cell death and disturbs the 
regeneration process after injury (Fausto, 2000), so NRF2 is essential to protect the liver 
against possible injuries caused by oxidative stress. It was reported that pharmacological 
activation of Nrf2, for example, by synthetic triterpenoids or avicins, could be a promising 
new strategy to improve regeneration in patients with acute or chronic liver damage 
(Hanausek et al., 2001; Hyer et al., 2005; Liby et al., 2005). In the current study, ALT 
activity in serum, a marker of liver damage, was not augmented in Nrf2-/- and Nrf2/Hfe-/- 
mice. However, the number of TUNEL-positive cells and the degree of necrosis were 
significantly increased in Nrf2/Hfe-/- livers, indicating that double knockout mice had more 
hepatic cell death. This study showed that the suppression of NRF2 leads to 
spontaneous liver damage in the mouse model of HH (Hfe-/-), which suggests that NRF2 
may also play an important hepatoprotectant role in HH patients. 
 
Human study 
It is known that oxidative stress may aggravate the clinical expression of HH 
(Pietrangelo, 2010). NRF2 is one key transcription factor involved in the antioxidant 
defense and there are strong associations between NRF2 sequence variations and 
disease risks (Cho, 2013). In this work we aimed to determine if SNPs in the promoter 
region of NRF2 gene could influence the severity of HH. For that purpose we estimated 
allele frequencies of known SNPs in the NRF2 promoter region in a large cohort of 
clinically well characterized HH patients and analysed both allele and genotype 
frequencies in relation to a set of clinical relevant variables.  
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Patients in our study presented elevated levels of ferritin and transferrin saturation, 
typical features of HH patients (Beutler, 2006) that are indicative of systemic iron 
overload. The severity of the iron overload ranged from moderate to severe. In terms of 
clinical manifestations, skin pigmentation was the most common one (17.9%), followed 
by cirrhosis (21.4%), arthropathy (16.4%), diabetes (4.5%) and hypogonadism (1.5%). 
When comparing the frequencies of Rs35652124, Rs6706649, Rs150648896 and 
Rs6721961 SNPs between the total 97 DNA samples from unrelated subjects and the 
ones reported in Ensembl for the European population, no statistically significant 
differences were observed. Moreover, when comparing the frequency of each SNP in 
patients clinically well characterized (n = 57) according to the expression of the disease, 
also no significant differences were found indicating that, in general, none of the studied 
SNPs per se prompts the patients to develop a specific clinical manifestation. 
Nevertheless, the frequency of the allele T in Rs35652124 SNP was increased in 
patients with cirrhosis and in symptomatic patients in general, when compared to patients 
without cirrhosis and without any clinical manifestations. To further clarify this question, 
we compared genotypes homozygous for the allele T in Rs35652124 SNP (Total TT) 
and genotypes homozygous/heterozygous for the allele C in Rs35652124 SNP (Total 
with C) in a subgroup of patients (n = 36) more strictly selected in terms of clinical 
variables. We then observed that frequency of cirrhosis was significantly increased in 
Total TT when compared to Total with CC genotypes and, although not statistically 
significant, symptomatic patients in general were also more common in Total TT 
genotypes. One should note that TBIS were also significantly increased in Total TT 
genotypes, therefore at this stage we cannot distinguish the relative impact of genotype 
and/or iron overload in the frequency of cirrhosis. Further extended studies, with a larger 
sample of patients, are needed to clarify that question. We can exclude, however, the 
impact of CD8+ T lymphocyte numbers on the results observed. It is known that low 
numbers of CD8+ T-lymphocytes are associated with a more severe iron overload and 
clinical expression in HH patients (Cruz et al., 2006). Since no significant differences 
were found in the CD8 phenotype between Total TT and Total with C genotypes, we can 
exclude CD8+ T-lymphocytes as the origin of the different clinical manifestation between 
the two groups. 
It is worth noting that the Rs35652124 T allele, which was found here associated with 
a more severe clinical expression, is the most frequent in the normal European 
population. If natural selection favored this allele in normal populations, we would not 
expect it have appeared as a particularly deleterious genotype in patients with HH, where 
it is also naturally more common. On the contrary, we hypothesize that the rarer allele C 
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in Rs35652124 SNP may act as a putative protective allele in HH, since, in our cohort, 
patients with this genotype had a less severe clinical picture. The Rs35652124 SNP has 
been previously reported to be a functional SNP predicted to affect Nrf2 myeloid zinc 
finger 1 (MZF1) promoter binding site. More specifically, the Rs35652124 C allele was 
shown to reduce the transcription activity of Nrf2 in a Luciferase activity assay (Marzec 
et al., 2007), presumably resulting in decreased Nrf2-dependent gene transcription. 
Interestingly, a study by von Otter et al., 2014 implicated Rs35652124 SNP in the 
progression of Parkinson’s disease showing that the Rs35652124 T allele was part of a 
protective haplotype that was associated with decreased risk and later onset of 
Parkinson’s disease (von Otter et al., 2014). How could differences in the transcription 
activity of NRF2 affect iron metabolism and the clinical consequences of HH, this is 
certainly a subject of great interest for future research in the iron biology field. 
 
Study limitations 
We acknowledge that the human study has two important limitations. One is the small 
sample size. More patients must be recruited in future in order to gain statistical power 
and hence augment the chances of finding significant associations between NRF2 SNPs 
and the clinical manifestation of HH. We should stress, however, that the reduction in 
the sample size from the original total number of patients genotyped was done with the 
objective of maintaining highly rigorous and strict clinical criteria. The second limitation 
of the study was the fact that we have only analyzed SNPs present in the promoter region 
of the NRF2 gene. Even though there is evidence in the literature linking Rs35652124, 
Rs6706649, Rs150648896 and Rs6721961 SNPs to phenotype-variants of certain 
diseases, it would be interesting to also study polymorphisms in the coding region of the 
NRF2 gene, by TaqMan Allelic Discrimination Assay, a multiplexed end-point assay that 
detects variants of a single nucleic acid sequence, or by sequencing the exons and exon-
flanking regions. 
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Conclusions 
In this study, Hfe-/- mice were used as a model of HH, mimicking what happens in patients 
homozygous for the HFE C282Y mutation. It is known that the lack of the Hfe gene leads 
to iron overload. The liver is capable of accumulating high amounts of iron and, in turn, 
iron is capable of generating ROS, leading to oxidative stress. Oxidative stress, in the 
absence of proper antioxidant defense, can lead to liver damage. NRF2 is the key 
transcription factor that regulates the antioxidant defense. Nrf2/Hfe-/- mice thus represent 
what happens to HH patients in the absence of an appropriate antioxidant defense. 
In our study, Nrf2/Hfe-/- mice were mildly anemic. Even if we could not determine the 
exact source of the anemia, we suppose that the lack of both Nrf2 and Hfe genes may 
have contributed to this finding, as Hfe gene is essential to balance the iron uptake by 
RBC and Nrf2 gene is necessary to increase RBC survival in the presence of ROS. 
Nrf2/Hfe-/- mice were also hypoglycemic. We hypothesized that the hypoglycemia at 
starvation could be a consequence of the worse body condition of Nrf2/Hfe-/- mice, as 
they presented the lowest weight. 
Nrf2/Hfe-/- mice presented lower levels of serum iron and transferrin saturation than 
Hfe-/- mice. The lack of NRF2 seems to have no influence on these parameters, since 
identical values were observed in Nrf2-/- and WT mice. The low serum iron and transferrin 
saturation of Nrf2/Hfe-/- mice were possibly a consequence of the anemia, as a decrease 
in erythrophagocytosis would be expected to decrease iron liberation into the 
bloodstream. An increase in bone marrow iron demand would also be expected to 
diminish the iron in circulation. In Nrf2/Hfe-/- mice, iron deposits were observed in the 
sinusoidal cells, contrary to the exclusive iron deposition in the liver parenchyma in Hfe-
/- mice. NRF2 thus seems to modulate iron metabolism in Hfe-/- mice, by shifting iron 
deposition from the liver parenchyma to the sinusoidal cells.  
Nrf2 -/- and Nrf2/Hfe-/- livers presented significantly decreased transcript levels of Nqo1 
when compared to WT and Hfe-/- mice, confirming that the NRF2 signaling pathway was 
not being activated, due to the lack of functional NRF2 in these animals. Besides, the 
GSH/GSSG ratio was significantly decreased in Nrf2-/- livers when compared to Hfe-/- 
livers. These data indicate that Nrf2-/- mice are under more oxidative stress than Hfe-/- 
mice, which reinforces the importance of NRF2 in the antioxidant defense. It is worth 
noting that MDA concentration of the four genotypes was not statistically different, 
suggesting that the occurrence of lipid peroxidation may be a consequence of the late 
age of the model, as the markers of lipid peroxidation tend to augment with age. 
Mild liver inflammation was detected in mice of the four genotypes, with no significant 
differences between the experimental groups. The low levels of inflammation are thus 
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likely to be a consequence of the advanced age of the model rather than a consequence 
of the genotype. On the other hand, steatosis was significantly augmented in Hfe-/- livers, 
but not in Nrf2/Hfe-/- livers, when compared to WT and Nrf2-/- livers. We speculate that 
the absence of steatosis in Nrf2/Hfe-/- mice may be a consequence of their low body 
weight/condition. 
The amount of non-heme Fe present in the livers of Hfe-/- and Nrf2/Hfe-/- mice was 
very similar, but markers of liver fibrosis and the degree of liver fibrosis were augmented 
only in Nrf2/Hfe-/- livers. Likewise, the number of TUNEL-positive cells and the degree of 
necrosis were significantly increased only in Nrf2/Hfe-/- livers, indicating increased 
hepatic cell death. Overall, we conclude that the suppression of NRF2 leads to 
spontaneous liver damage in Hfe-/- mice, the mouse model of HH. Based on this 
evidence, we hypothesize that NRF2 may also play an important role in HH patients, 
protecting hepatic cells from the damage caused by excessive iron. 
To address that hypothesis, we asked if some SNP variants in the NRF2 promoter 
region could prompt HH patients to develop a more severe phenotype of the disease. 
Our results indicate that none of the SNPs alone prompts the patients to develop a 
specific clinical manifestation, but it showed that patients carrying the allele C in 
Rs35652124 SNP are somehow protected from clinical manifestations of HH. Further 
studies are required to overcome the present sample limitations and to determine if the 
here observed effect is the result of a lower accumulation of iron in allele C carriers or 
from an enhanced antioxidant response in these subjects.  
In conclusion, the current study shows that NRF2 has an important hepatoprotective 
role in the animal model of HH and suggests that gene variants may be also implicated 
in the clinical course of the human disease. The possibility that SNPs in the NRF2 gene 
may modify HH penetrance warrants further investigation. 
 
Future perspectives  
Concerning the animal study, the anemia and hypoglycemia at starvation of the Nrf2/Hfe-
/- mice need to be clarified. The low body weight/condition of Nrf2/Hfe-/- mice also needs 
to be investigated, to determine if the lack of both Nrf2 and Hfe genes combined with the 
advanced age of the model is by itself the origin of this poor condition. The role of NRF2 
as a modulator of iron distribution in Hfe-/- mice and the mechanisms how NRF2 protects 
these mice against liver damage also need to be clarified. In what concerns the human 
study, more SNPs should be studied (including coding regions of the NRF2 gene) and 
the sample size should be increased, in order to determine if there is an association 
between NRF2 genetic variants and clinical manifestations of HH.  
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